Author: "M. Matusiak" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"M. Matusiak"' showing total 119 results

Start Over Author "M. Matusiak"

119 results on '"M. Matusiak"'

1. Production of antihydrogen atoms by 6 keV antiprotons through a positronium cloud

Author: P. Adrich, P. Blumer, G. Caratsch, M. Chung, P. Cladé, P. Comini, P. Crivelli, O. Dalkarov, P. Debu, A. Douillet, D. Drapier, P. Froelich, N. Garroum, S. Guellati-Khelifa, J. Guyomard, P.-A. Hervieux, L. Hilico, P. Indelicato, S. Jonsell, J.-P. Karr, B. Kim, S. Kim, E.-S. Kim, Y. J. Ko, T. Kosinski, N. Kuroda, B. M. Latacz, B. Lee, H. Lee, J. Lee, E. Lim, L. Liszkay, D. Lunney, G. Manfredi, B. Mansoulié, M. Matusiak, V. Nesvizhevsky, F. Nez, S. Niang, B. Ohayon, K. Park, N. Paul, P. Pérez, C. Regenfus, S. Reynaud, C. Roumegou, J.-Y. Roussé, Y. Sacquin, G. Sadowski, J. Sarkisyan, M. Sato, F. Schmidt-Kaler, M. Staszczak, K. Szymczyk, T. A. Tanaka, B. Tuchming, B. Vallage, A. Voronin, D. P. van der Werf, A. Welker, D. Won, S. Wronka, Y. Yamazaki, K.-H. Yoo, and P. Yzombard
Subjects: Astrophysics, QB460-466, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Abstract: Abstract We report on the first production of an antihydrogen beam by charge exchange of 6.1 keV antiprotons with a cloud of positronium in the GBAR experiment at CERN. The 100 keV antiproton beam delivered by the AD/ELENA facility was further decelerated with a pulsed drift tube. A 9 MeV electron beam from a linear accelerator produced a low energy positron beam. The positrons were accumulated in a set of two Penning–Malmberg traps. The positronium target cloud resulted from the conversion of the positrons extracted from the traps. The antiproton beam was steered onto this positronium cloud to produce the antiatoms. We observe an excess over background indicating antihydrogen production with a significance of 3–4 standard deviations.
Published: 2023
Full Text: View/download PDF

2. Publisher Erratum: Production of antihydrogen atoms by 6 keV antiprotons through a positronium cloud

Author: P. Adrich, P. Blumer, G. Caratsch, M. Chung, P. Cladé, P. Comini, P. Crivelli, O. Dalkarov, P. Debu, A. Douillet, D. Drapier, P. Froelich, N. Garroum, S. Guellati-Khelifa, J. Guyomard, P.-A. Hervieux, L. Hilico, P. Indelicato, S. Jonsell, J.-P. Karr, B. Kim, S. Kim, E.-S. Kim, Y. J. Ko, T. Kosinski, N. Kuroda, B. M. Latacz, B. Lee, H. Lee, J. Lee, E. Lim, L. Liszkay, D. Lunney, G. Manfredi, B. Mansoulié, M. Matusiak, V. Nesvizhevsky, F. Nez, S. Niang, B. Ohayon, K. Park, N. Paul, P. Pérez, C. Regenfus, S. Reynaud, C. Roumegou, J.-Y. Roussé, Y. Sacquin, G. Sadowski, J. Sarkisyan, M. Sato, F. Schmidt-Kaler, M. Staszczak, K. Szymczyk, T. A. Tanaka, B. Tuchming, B. Vallage, A. Voronin, D. P. van der Werf, A. Welker, D. Won, S. Wronka, Y. Yamazaki, K.-H. Yoo, and P. Yzombard
Subjects: Astrophysics, QB460-466, Nuclear and particle physics. Atomic energy. Radioactivity, QC770-798
Published: 2023
Full Text: View/download PDF

3. CHARACTERISTICS OF NATURAL OAK FORESTS OF IN SE 'KHMILNYTSKE LISOVE HOSPODARSTVO' AND IMPLEMENTATION OF MEASURES FOR THEIR REGENERATION

Author: O. Vasylevskyi, I. Neyko, Y. Yelisavenko, and M. Matusiak
Subjects: common oak, natural plantings, modal stands, high-bonitat stands, forest types, reforestation, natural regeneration, Agriculture
Abstract: As a consequence of the intensive economic use of oak forests in the region, the share of stands of natural origin is significantly reduced, which requires an in-depth study of their condition, productivity, and natural restoration processes. The purpose of this study is to investigate the state, structure, and reforestation processes of oak forests for their further natural reproduction. Generally accepted methods in forestry and comparative ecology were used to compare the dynamics and condition of the studied stands with the reference ones. The paper presents the findings of the study of the productivity and state of natural forests within the state enterprise "Khmilnytske lisove hospodarstvo". It was found out that natural oak stands are represented by 7 forest types, mainly in fresh hornbeam oak forest (area – 471 hectares). According to the results obtained, it was found that natural oak stands of vegetative origin predominate within the studied enterprise (528.6 ha). They are mainly represented by forests of the 11th age class (188.0 ha). High-bonitat oak forests of the 1st quality class predominate. Mature and over-mature stands have slightly lower productivity (2nd quality class, stand density of 0.6-0.7). The largest total reserve is characterised by stands of the 11th age class. The maximum average reserves are typical for stands of the 9th age class (290 m3/ha). The greatest share of oak in stand composition (9-10 units) was found in stands of 9-10 age classes. The study shows that the natural renewal of oak is concentrated mainly in fresh sudubrava (fresh hornbeam sudubrava) in plantings in the presence of Scots pine and common oak. The density of natural renewal is 1-3 thousand units/ha. The practical value of the study is conditioned by the possibility of introducing the basic principles of forestry aimed at growing stable high-yield stands of common oak through more complete utilisation of natural renewal.
Published: 2021
Full Text: View/download PDF

4. Fractional discrete model of an electrical drive with brushless micro-motor

Author: M. Matusiak, M. Bąkała, R. Wojciechowski, and P. Ostalczyk
Subjects: system modeling, system identification, fractional order calculus, Technology, Technology (General), T1-995
Abstract: The use of fractional-order calculus for system modeling is a good alternative to well-known classic integer-order methods, primarily due to the precision with which the modeled object may be mapped. In this study, we created integer and fractional discrete models of a real object – a highspeed brushless micro-motor. The accuracy of the models was verified and compared.
Published: 2020
Full Text: View/download PDF

5. EVALUATION OF WINTER-RESISTANCE KINDS OF MAGNOLIA L. IN THE CONDITIONS OF THE BIOSTATSIONAR VINNYTSIA NATIONAL AGRARIAN UNIVERSITY

Author: M. Matusiak
Subjects: winter hardiness, introduction, growing season, magnolia, phenological observations, landscaping., Agriculture
Abstract: The most sensitive to temperature changes, especially in winter and spring, are annual magnolia shoots, as evidenced by the formation of frost on plants. Therefore, for the successful introduction of magnolia in the temperate climate of Ukraine, it is necessary to select species capable of restructuring their physiological processes in the direction of increasing cold resistance, which will facilitate their adaptation in new conditions. The analysis conducted to determine the features of winter-hardy species of the Magnolia genus in the Vinnitsa conditions shows that not all species of the genus can tolerate the climatic conditions of the region, and especially the winter period. According to the conducted observations, the beginning of shoot growth in the magnolia in the conditions of Vinnitsa is observed during the month of April. In species such as Magnolia kobus D.C., Magnolia obovata Thunb., Magnolia acuminata L., shoot growth begins in the first decade of Аpril. In the second decade of April, the growth of shoots of Magnolia Soulangeanа Soul. begins. In the third decade of April – the first decade of May, shoots begin to grow actively in Magnolia tripetala L. The terms of the end of the growth period and its duration vary greatly and depend on the geographical origin and species-specific features of the species, but, mainly, the magnolias introduced in Vinnitsa, finish their increment in length in the II–III decade of September – Magnolia soulangeanа Soul., Magnolia tripetala L. In the species Magnolia kobus DC, Magnolia obovata Thunb., Magnolia acuminata L. shoot growth ends in the third decade of August and the first decade of September. According to the 7-point Woolf winter hardiness scale, it was found that the highest winter hardiness in the conditions of VNAU biostationary (1 point) is possessed by species such as magnolia (M. obovata Thunb.), Kobus (M. kobus DC) and pointed (M. acuminata L.). Somewhat less winter hardiness is characterized by (2 points) Magnolia Soulange (M. soulangiana Soul.), That is, in winter freezing was less than 50 % of annual shoots, and the damage of annual shoots with low negative temperatures was 3–5 cm. The lowest winter hardiness in biostable conditions UNAU (5 points) is noted magnolia triple (M. tripetala L.), the damage of the plant was up to the level of snow cover (almost 80 % of habitus). Deciduous species of the genus are winter-hardy, but in severe winters, such as Magnolia Sulange (M. soulangiana Soul.), Stellate (M. stellata (Siebold & Zucc.) Maxim.), Flower buds and annual shoots can be damaged. It is also important that with age magnolia increases not only the abundance of flowering, its duration, but also winter hardiness.
Published: 2020
Full Text: View/download PDF

6. Radiologic measurement of cochlea and hearing preservation rate using slim straight electrode (CI422) and round window approach

Author: H. Skarzynski, M. Matusiak, M. Furmanek, A. Pilka, E. Wlodarczyk, M. Oldak, and P. H. Skarzynski
Subjects: Otorhinolaryngology, RF1-547
Published: 2018
Full Text: View/download PDF

7. Pseudogap phase of cuprate superconductors confined by Fermi surface topology

Author: N. Doiron-Leyraud, O. Cyr-Choinière, S. Badoux, A. Ataei, C. Collignon, A. Gourgout, S. Dufour-Beauséjour, F. F. Tafti, F. Laliberté, M.-E. Boulanger, M. Matusiak, D. Graf, M. Kim, J.-S. Zhou, N. Momono, T. Kurosawa, H. Takagi, and Louis Taillefer
Subjects: Science
Abstract: High-temperature superconductors exhibit pseudogap behaviour that remains of unknown origin, despite many years of intensive study. Here the authors study the onset of the pseudogap under pressure, providing evidence that it requires a hole-like Fermi surface and constraining future theoretical developments.
Published: 2017
Full Text: View/download PDF

8. Opioid Prescribing in United States Health Systems, 2015 to 2019

Author: Katie J. Suda, Mina Tadrous, Linda M. Matusiak, and Tumader Khouja
Subjects: medicine.medical_specialty, Databases, Factual, Pharmacy, Opioid prescribing, Fentanyl, 03 medical and health sciences, 0302 clinical medicine, medicine, 030212 general & internal medicine, Practice Patterns, Physicians', Medical prescription, business.industry, 030503 health policy & services, Health Policy, Public Health, Environmental and Occupational Health, United States, Analgesics, Opioid, Opioid, Hydrocodone, Emergency medicine, 0305 other medical science, business, Delivery of Health Care, Oxycodone, medicine.drug, Healthcare system
Abstract: Objectives Health systems (nonfederal hospitals and clinics) are the second major source for drug expenditure in the United States. Opioids prescribed in these healthcare settings are commonly short-acting opioids that can lead to persistent opioid use. Nevertheless, there are no national data that describe trends in opioid use and the associated expenditure in health systems. Therefore, the objective of this article was to describe opioid use and expenditures in US health systems from 2015 to 2019. Methods We used data from IQVIA National Sales Perspectives to describe prescription opioid expenditure and use in health systems (nonfederal hospitals and clinics). Results Over the 5-year study period, health systems dispensed a total of 6.55 billion units of opioids (26.88% decrease) with an associated expenditure of $3.33 billion (26.78% decrease). Relative to all opioid formulations in our study, oxycodone, hydrocodone, and fentanyl were the opioids with the highest use in US health systems. All opioid prescriptions decreased except fentanyl use, which increased by 29.80% in clinics. The use of abuse-deterrent formulations of opioids decreased by 51.00% over the study period, although the decrease seems to be driven mainly by long-acting oxycodone (brand name Oxycontin). Conclusions Opioid use and expenditures in health systems have been decreasing following national trends from retail pharmacies. Nevertheless, fentanyl use increased in clinics and was prescribed at higher proportions in nonfederal hospitals than other opioids, which warrants further investigation.
Published: 2021

9. Supernova model discrimination with hyper-kamiokande

Author: Y. Nagao, H. Tanaka, A. Minamino, B. Navarro-Garcia, Z. Xie, L. Nascimento Machado, J. Lagoda, M. Shinoki, S. Cuen-Rochin, Arman Esmaili, F. Ballester, S. Parsa, N. McCauley, Jung-Hyun Kim, K. Frankiewicz, L. L. Kormos, Masaki Ishitsuka, M. Malek, V. Valentino, N. Kazarian, T. Wachala, E. Drakopoulou, G. Grella, V. Paolone, L. F. Thompson, A. K. Tomatani-Sánchez, A. Blanchet, R. A. Wendell, John Ellis, J. Y. Kim, N. W. Prouse, O. V. Mineev, M. R. Vagins, T. Boschi, T. Lindner, J. González-Nuevo, Hiroshi Ito, N. Skrobova, M. La Commara, L. Gialanella, F. Orozco-Luna, T. Kumita, A. Garfagnini, S. H. Jeon, A. Dergacheva, Hiroaki Menjo, A. T. Suzuki, K. Okamoto, C. E. R. Naseby, J. F. Martin, T. Iijima, M. Mezzetto, G. Ricciardi, J. R. Wilson, P. Gumplinger, Y. Takemoto, G. Galinski, K. Zaremba, T. Nakadaira, D. Vivolo, A. Carroll, C. Vilela, A. Blondel, A. Rychter, T. A. Doyle, C. Garde, G. De Rosa, A. Oshlianskyi, Hiroyuki Sekiya, R. Matsumoto, G. Pastuszak, P. J. Rajda, F. Monrabal, Yoichi Asaoka, G. Díaz López, K. L. Stankevich, C. D. Shin, Y. Fukuda, Yuto Ashida, Michal Malinský, T. Suganuma, B. Radics, Kohta Murase, Marco Grassi, P. Mehta, F. Cafagna, Ahmed Ali, L. Koerich, Vincenzo Berardi, Etam Noah, F. J. P. Soler, Alan Cosimo Ruggeri, M. Kekic, G. Vasseur, S. Wronka, M. Thiesse, B. Ferrazzi, K. Iwamoto, Yu. Kudenko, Atsushi Takeda, Kendall Mahn, David Hadley, B. Roskovec, M. Bergevin, A. Korzenev, J.J. Gómez-Cadenas, M. Batkiewicz-Kwasniak, M. Tzanov, M. Ikeda, Federico Sanchez, W. Obrębski, H. S. Jo, Y. Takeuchi, Piotr Kalaczyński, S. Chakraborty, J. C. Nugent, S. King, P. Paganini, M. Miura, F. Ameli, D. N. Yeum, C. J. Metelko, Akito Araya, T. Kajita, M. Tanaka, I. T. Lim, L. Mellet, S. Y. Kim, S. Bolognesi, A. Bravar, J. S. Jang, D. Svirida, A. Fiorentini, J. Renner, M. Chabera, L. O'Sullivan, V. Herrero, F. Iacob, K. Nakamura, Ko Okumura, Lukasz Stawarz, N. Ogawa, Laura Bonavera, Y. Maekawa, Takatomi Yano, Ll. Marti, H. J. Rose, S. El Hedri, L. Maret, G. Zarnecki, L. Bernard, S. H. Seo, H. Nakamura, H. Ozaki, A. P. Kryukov, A. Popov, Hisakazu Minakata, M. Buizza Avanzini, P. Sarmah, K. Martens, Sergio Luis Suárez Gómez, Hiroaki Aihara, V. Lezaun, G. A. Cowan, C. Riccio, S. Garode, R. Akutsu, M. Lamers James, T. Nicholls, I. Alekseev, K. Kowalik, J. Kasperek, T. Zakrzewski, S. B. Kim, T. Kutter, Evan O'Connor, B. Jamieson, F. Nova, M. Barbi, Xianguo Lu, Y. Sonoda, M. Friend, Teppei Katori, L. H. V. Anthony, A. Shaikhiev, C. J. Densham, V. Gousy-Leblanc, I. Bandac, J. H. Choi, S. Sano, A. K. Ichikawa, Magda Cicerchia, S. Valder, S. Roth, J. Kameda, M. Zito, A. Vijayvargi, S. Nakai, Y. Kotsar, K. M. Tsui, K. Hoshina, K. K. Joo, C. Pastore, T. Marchi, K. Niewczas, K. Nakayoshi, G. Fiorillo, C. McGrew, P. F. Loverre, S. Playfer, G.D. Barr, L. Labarga, T. Kobayashi, E. S. Pinzon Guerra, André Rubbia, D. Karlen, Th. A. Mueller, L. Koch, F. J. Mora, M. M. Khabibullin, Hidekazu Kakuno, Yoshitaka Itow, H. K. Tanaka, P. Adrich, Jeong-Eun Lee, S. Samani, M. G. Catanesi, M. Yu, M. J. Wilking, Robert Svoboda, P. Mijakowski, N. Kolev, Yu. Onishchuk, A. Kato, J. M. Poutissou, C. Bronner, Yutaka Nakajima, B. Richards, C. Ruggles, M. Needham, P. Jonsson, Y. Hayato, S. Mine, A. Konaka, L. Munteanu, Kunio Inoue, O. Drapier, Kenneth Long, M. McCarthy, T. Kinoshita, G. Tortone, Yuuki Nakano, T. Feusels, N. Izumi, Reetanjali Moharana, T. Dealtry, S. Hassani, G. Pronost, K. Sakashita, J. G. Learned, H. M. O'Keeffe, Shintaro Ito, E. Rondio, Toru Ogitsu, D. A. Patel, Tatiana Ovsiannikova, M. Guigue, Yusuke Koshio, T. Matsubara, S. M. Stellacci, R. J. Wilkes, G. Santucci, S. Y. Suzuki, S. D. Rountree, K. Zietara, A. A. Quiroga, M. Jakkapu, A. Boiano, L. Berns, M. O. Wascko, M. M. Vyalkov, K. Porwit, M. Taani, A. Evangelisti, I. Sashima, Michal Dziewiecki, J. Feng, Y. Seiya, M. Yonenaga, B. Spisso, B. W. Pointon, C. M. Mollo, N. Booth, S. V. Cao, N. Ospina, A. J. Finch, V. Takhistov, E. Radicioni, P. Przewlocki, S. Nakayama, S. Yen, T. Sekiguchi, Yudai Suwa, J. M. Calvo-Mozota, S. Zsoldos, C. Checchia, M. Posiadala-Zezula, E. O'Sullivan, Janusz Marzec, F. Retiere, Jan T. Sobczyk, P. Migliozzi, S. Borjabad, I. Di Palma, John Hill, K. A. Kouzakov, D. L. Wark, L. Cook, D. Sgalaberna, E. W. Miller, M. Lamoureux, M. Y. Pac, S. Russo, S. L. Cartwright, Yasunari Suzuki, D. Bose, B. Zaldivar, D. Martin, Dongsu Ryu, Z. Shan, S. Miki, M. Jiang, J. Kisiel, N. Yershov, M. Matusiak, C. Pea-Garay, K. Sato, Jesús Daniel Santos, Y. Yamaguchi, D. Bravo-Berguo, Chad Finley, T. Tashiro, Lawrence D. Brown, A. Gorin, Hiromasa Tanaka, M. Ziembicki, T. Vladisavljevic, J. Zalipska, J. Insler, C. Yanagisawa, Abinash Medhi, L. Kravchuk, W. Idrissi Ibnsalih, Hirokazu Ishino, J. Bian, K. Magar, S. Cebrian, Philippe Mermod, R. Gornea, Juan Pedro Ochoa-Ricoux, Sergei Fedotov, S. Izumiyama, C. Bozza, R. Esteve, Seiko Hirota, T. Tsukamoto, K. Skwarczynski, E. De la Fuente, T. Kikawa, M. Gonin, J. Xia, Intae Yu, Gareth J. Barker, A. Marinelli, E. Kearns, L. Lavitola, Michal Ostrowski, N. Deshmukh, Y. Kataoka, F. d. M. Blaszczyk, Carsten Rott, C. Mariani, T. Ishida, Roberto Spina, J. W. Seo, Masashi Yokoyama, F. Gramegna, K. Hultqvist, G. Collazuol, P. Spradlin, Gus Sinnis, A. Takenaka, T. Xin, M. Bellato, Yuki Fujii, Mark Scott, J. A. Hernando-Morata, P. Ferrario, A. Buchowicz, S. J. Jenkins, J. Walker, J. Toledo, Pablo Fernandez, Sandhya Choubey, S. Emery, A. Mefodiev, R.P. Kurjata, M. Mongelli, J. Dumarchez, Tsuyoshi Nakaya, M. Antonova, M. Danilov, M. Feely, A. Holin, Ara Ioannisian, B. A. Popov, K Stopa, W. G. S. Vinning, M. L. Sánchez, Masato Shiozawa, L. Ludovici, J. Gao, S. Bhadra, Koji Ishidoshiro, Hiroshi Nunokawa, V. Aushev, M. Hartz, I. Shimizu, C. S. Moon, M. B. Smy, S. Matsuno, I. Anghel, J. Migenda, T. Mondal, F. Di Lodovico, M. Tada, D. J. Payne, M. Kuze, N. C. Hastings, P. Di Meo, Y. Nishimura, M. Inomoto, L. Magaletti, C. Giganti, A. Klekotko, Patrick Dunne, J. Yoo, M. C. Sanchez, A. N. Khotjantsev, Kyujin Kwak, Lars Eklund, M. Lawe, A. Mitra, H. W. Sobel, Jürgen Pozimski, Yasuhiro Makida, A. Bubak, Jaroslaw Pasternak, B. Quilain, R. Leitner, Marco Laveder, J. P. Coleman, N. F. Calabria, H. I. Jang, S. B. Boyd, Moon Moon Devi, M. Fitton, M. Harada, Artur F. Izmaylov, J. McElwee, Shunsaku Horiuchi, P. de Perio, K. Nakagiri, Y. Kano, M. Rescigno, S. Moriyama, Masayuki Nakahata, C. Pidcott, Y. Uchida, V. Palladino, A. Longhin, A. Shaykina, Michelangelo Pari, Akimichi Taketa, Yuichi Oyama, S. Suvorov, R. P. Litchfield, D. H. Moon, Katsuki Hiraide, M. Pavin, M. Koga, R. B. Vogelaar, Enrique Fernandez-Martinez, B. L. Hartfiel, Koji Yamamoto, K. Ohta, K. Abe, Alexander Studenikin, E. Mazzucato, Elisa Bernardini, Abe, K., Adrich, P., Aihara, H., Akutsu, R., Alekseev, I., Ali, A., Ameli, F., Anghel, I., Anthony, L. H. V., Antonova, M., Araya, A., Asaoka, Y., Ashida, Y., Aushev, V., Ballester, F., Bandac, I., Barbi, M., Barker, G. J., Barr, G., Batkiewicz-Kwasniak, M., Bellato, M., Berardi, V., Bergevin, M., Bernard, L., Bernardini, E., Berns, L., Bhadra, S., Bian, J., Blanchet, A., Blaszczyk, F. D. M., Blondel, A., Boiano, A., Bolognesi, S., Bonavera, L., Booth, N., Borjabad, S., Boschi, T., Bose, D., Boyd, S. B., Bozza, C., Bravar, A., Bravo-Berguo, D., Bronner, C., Brown, L., Bubak, A., Buchowicz, A., Buizza Avanzini, M., Cafagna, F. S., Calabria, N. F., Calvo-Mozota, J. M., Cao, S., Cartwright, S. L., Carroll, A., Catanesi, M. G., Cebrian, S., Chabera, M., Chakraborty, S., Checchia, C., Choi, J. H., Choubey, S., Cicerchia, M., Coleman, J., Collazuol, G., Cook, L., Cowan, G., Cuen-Rochin, S., Danilov, M., Diaz Lopez, G., De La Fuente, E., De Perio, P., De Rosa, G., Dealtry, T., Densham, C. J., Dergacheva, A., Deshmukh, N., Devi, M. M., Di Lodovico, F., Di Meo, P., Di Palma, I., Doyle, T. A., Drakopoulou, E., Drapier, O., Dumarchez, J., Dunne, P., Dziewiecki, M., Eklund, L., El Hedri, S., Ellis, J., Emery, S., Esmaili, A., Esteve, R., Evangelisti, A., Feely, M., Fedotov, S., Feng, J., Fernandez, P., Fernandez-Martinez, E., Ferrario, P., Ferrazzi, B., Feusels, T., Finch, A., Finley, C., Fiorentini, A., Fiorillo, G., Fitton, M., Frankiewicz, K., Friend, M., Fujii, Y., Fukuda, Y., Galinski, G., Gao, J., Garde, C., Garfagnini, A., Garode, S., Gialanella, L., Giganti, C., Gomez-Cadenas, J. J., Gonin, M., Gonzalez-Nuevo, J., Gorin, A., Gornea, R., Gousy-Leblanc, V., Gramegna, F., Grassi, M., Grella, G., Guigue, M., Gumplinger, P., Hadley, D. R., Harada, M., Hartfiel, B., Hartz, M., Hassani, S., Hastings, N. C., Hayato, Y., Hernando-Morata, J. A., Herrero, V., Hill, J., Hiraide, K., Hirota, S., Holin, A., Horiuchi, S., Hoshina, K., Hultqvist, K., Iacob, F., Ichikawa, A. K., Idrissi Ibnsalih, W., Iijima, T., Ikeda, M., Inomoto, M., Inoue, K., Insler, J., Ioannisian, A., Ishida, T., Ishidoshiro, K., Ishino, H., Ishitsuka, M., Ito, H., Ito, S., Itow, Y., Iwamoto, K., Izmaylov, A., Izumi, N., Izumiyama, S., Jakkapu, M., Jamieson, B., Jang, H. I., Jang, J. S., Jenkins, S. J., Jeon, S. H., Jiang, M., Jo, H. S., Jonsson, P., Joo, K. K., Kajita, T., Kakuno, H., Kameda, J., Kano, Y., Kalaczynski, P., Karlen, D., Kasperek, J., Kataoka, Y., Kato, A., Katori, T., Kazarian, N., Kearns, E., Khabibullin, M., Khotjantsev, A., Kikawa, T., Kekic, M., Kim, J. H., Kim, J. Y., Kim, S. B., Kim, S. Y., King, S., Kinoshita, T., Kisiel, J., Klekotko, A., Kobayashi, T., Koch, L., Koga, M., Koerich, L., Kolev, N., Konaka, A., Kormos, L. L., Koshio, Y., Korzenev, A., Kotsar, Y., Kouzakov, K. A., Kowalik, K. L., Kravchuk, L., Kryukov, A. P., Kudenko, Y., Kumita, T., Kurjata, R., Kutter, T., Kuze, M., Kwak, K., La Commara, M., Labarga, L., Lagoda, J., Lamers James, M., Lamoureux, M., Laveder, M., Lavitola, L., Lawe, M., Learned, J. G., Lee, J., Leitner, R., Lezaun, V., Lim, I. T., Lindner, T., Litchfield, R. P., Long, K. R., Longhin, A., Loverre, P., Lu, X., Ludovici, L., Maekawa, Y., Magaletti, L., Magar, K., Mahn, K., Makida, Y., Malek, M., Malinsky, M., Marchi, T., Maret, L., Mariani, C., Marinelli, A., Martens, K., Marti, L., Martin, J. F., Martin, D., Marzec, J., Matsubara, T., Matsumoto, R., Matsuno, S., Matusiak, M., Mazzucato, E., Mccarthy, M., Mccauley, N., Mcelwee, J., Mcgrew, C., Mefodiev, A., Medhi, A., Mehta, P., Mellet, L., Menjo, H., Mermod, P., Metelko, C., Mezzetto, M., Migenda, J., Migliozzi, P., Mijakowski, P., Miki, S., Miller, E. W., Minakata, H., Minamino, A., Mine, S., Mineev, O., Mitra, A., Miura, M., Moharana, R., Mollo, C. M., Mondal, T., Mongelli, M., Monrabal, F., Moon, D. H., Moon, C. S., Mora, F. J., Moriyama, S., Mueller, T. A., Munteanu, L., Murase, K., Nagao, Y., Nakadaira, T., Nakagiri, K., Nakahata, M., Nakai, S., Nakajima, Y., Nakamura, K., Nakamura, K. I., Nakamura, H., Nakano, Y., Nakaya, T., Nakayama, S., Nakayoshi, K., Nascimento Machado, L., Naseby, C. E. R., Navarro-Garcia, B., Needham, M., Nicholls, T., Niewczas, K., Nishimura, Y., Noah, E., Nova, F., Nugent, J. C., Nunokawa, H., Obrebski, W., Ochoa-Ricoux, J. P., O'Connor, E., Ogawa, N., Ogitsu, T., Ohta, K., Okamoto, K., O'Keeffe, H. M., Okumura, K., Onishchuk, Y., Orozco-Luna, F., Oshlianskyi, A., Ospina, N., Ostrowski, M., O'Sullivan, E., O'Sullivan, L., Ovsiannikova, T., Oyama, Y., Ozaki, H., Pac, M. Y., Paganini, P., Palladino, V., Paolone, V., Pari, M., Parsa, S., Pasternak, J., Pastore, C., Pastuszak, G., Patel, D. A., Pavin, M., Payne, D., Pea-Garay, C., Pidcott, C., Pinzon Guerra, E., Playfer, S., Pointon, B. W., Popov, A., Popov, B., Porwit, K., Posiadala-Zezula, M., Poutissou, J. -M., Pozimski, J., Pronost, G., Prouse, N. W., Przewlocki, P., Quilain, B., Quiroga, A. A., Radicioni, E., Radics, B., Rajda, P. J., Renner, J., Rescigno, M., Retiere, F., Ricciardi, G., Riccio, C., Richards, B., Rondio, E., Rose, H. J., Roskovec, B., Roth, S., Rott, C., Rountree, S. D., Rubbia, A., Ruggeri, A. C., Ruggles, C., Russo, S., Rychter, A., Ryu, D., Sakashita, K., Samani, S., Sanchez, F., Sanchez, M. L., Sanchez, M. C., Sano, S., Santos, J. D., Santucci, G., Sarmah, P., Sashima, I., Sato, K., Scott, M., Seiya, Y., Sekiguchi, T., Sekiya, H., Seo, J. W., Seo, S. H., Sgalaberna, D., Shaikhiev, A., Shan, Z., Shaykina, A., Shimizu, I., Shin, C. D., Shinoki, M., Shiozawa, M., Sinnis, G., Skrobova, N., Skwarczynski, K., Smy, M. B., Sobczyk, J., Sobel, H. W., Soler, F. J. P., Sonoda, Y., Spina, R., Spisso, B., Spradlin, P., Stankevich, K. L., Stawarz, L., Stellacci, S. M., Stopa, K., Studenikin, A. I., Suarez Gomez, S. L., Suganuma, T., Suvorov, S., Suwa, Y., Suzuki, A. T., Suzuki, S. Y., Suzuki, Y., Svirida, D., Svoboda, R., Taani, M., Tada, M., Takeda, A., Takemoto, Y., Takenaka, A., Taketa, A., Takeuchi, Y., Takhistov, V., Tanaka, H., Tanaka, H. A., Tanaka, H. I., Tanaka, M., Tashiro, T., Thiesse, M., Thompson, L. F., Toledo, J., Tomatani-Sanchez, A. K., Tortone, G., Tsui, K. M., Tsukamoto, T., Tzanov, M., Uchida, Y., Vagins, M. R., Valder, S., Valentino, V., Vasseur, G., Vijayvargi, A., Vilela, C., Vinning, W. G. S., Vivolo, D., Vladisavljevic, T., Vogelaar, R. B., Vyalkov, M. M., Wachala, T., Walker, J., Wark, D., Wascko, M. O., Wendell, R. A., Wilkes, R. J., Wilking, M. J., Wilson, J. R., Wronka, S., Xia, J., Xie, Z., Xin, T., Yamaguchi, Y., Yamamoto, K., Yanagisawa, C., Yano, T., Yen, S., Yershov, N., Yeum, D. N., Yokoyama, M., Yonenaga, M., Yoo, J., Yu, I., Yu, M., Zakrzewski, T., Zaldivar, B., Zalipska, J., Zaremba, K., Zarnecki, G., Ziembicki, M., Zietara, K., Zito, M., Zsoldos, S., Laboratoire Leprince-Ringuet (LLR), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE (UMR_7585)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Hyper-Kamiokande, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Physics - Instrumentation and Detectors, 09.- Desarrollar infraestructuras resilientes, promover la industrialización inclusiva y sostenible, y fomentar la innovación, KAMIOKANDE, Astrophysics, 01 natural sciences, neutrino: flux, High Energy Physics - Experiment, High Energy Physics - Experiment (hep-ex), neutrino, accretion, black hole, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Core-collapse supernovae, neutron star, Monte Carlo, physics.ins-det, 010303 astronomy & astrophysics, astro-ph.HE, High Energy Astrophysical Phenomena (astro-ph.HE), Physics, Instrumentation and Detectors (physics.ins-det), 16. Peace & justice, Supernova, neutrino: detector, 07.- Asegurar el acceso a energías asequibles, fiables, sostenibles y modernas para todos, supernova, neutrino astronomy, neutrino physics, Neutrino detector, Neutrino, Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - High Energy Astrophysical Phenomena, supernova: collapse, Astrophysics::High Energy Astrophysical Phenomena, FOS: Physical sciences, Observable universe, Astrophysics::Cosmology and Extragalactic Astrophysics, Hyper-Kamiokande, 0103 physical sciences, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], High energy physics, Instrumentation and Methods for Astrophysics (astro-ph.IM), High Energy Astrophysical Phenomena, Astrophysics::Galaxy Astrophysics, hep-ex, 010308 nuclear & particles physics, supernova: model, Astronomy and Astrophysics, Galaxy, Black hole, Neutron star, Space and Planetary Science, neutrino: burst, galaxy, Neutrino astronomy, [PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph], astro-ph.IM
Abstract: Autorzy: Abe K., Adrich P., Aihara H., Akutsu, R., Alekseev I., Ali A. , Ameli F., Anghel I., Anthony L. H. V., Antonova M. , Araya A., Asaoka Y., Ashida Y., Aushev V., Ballester F., Bandac I., Barbi M., Barker G. J., Barr G., Batkiewicz-Kwasniak M., Bellato M., Berardi V., Bergevin M., Bernard L., Bernardini E., Berns L., Bhadra S., Bian J., Blanchet A., Blaszczyk F. d. M., Blonde A., Boiano A., Bolognesi S., Bonavera L., Booth N., Borjabad S., Boschi, T., Bose D., Boyd S . B., Bozza C., Bravar A., Bravo-Berguño D., Bronner C., Brown L., Bubak Arkadiusz, Buchowicz A., Buizza Avanzini M., Cafagna F. S., Calabria N. F., Calvo-Mozota J. M., Cao S., Cartwright S.L., Carroll A., Catanesi M. G., Cebriàn, S., Chabera M., Chakraborty, S., Checchia C., Choi J.H., Choubey S., Cicerchia M., Coleman J., Collazuol G., Cook L., Cowan G., Cuen-Rochin, S., Danilov M., Díaz López G., De la Fuente E., de Perio P., De Rosa G., Dealtry T., Densham C. J., Dergacheva A., Deshmukh N., Devi M. M., Di Lodovico F., Di Meo, P., Di Palma I., Doyle T. A., Drakopoulou E., Drapier O., Dumarchez J., Dunne P., Dziewiecki M., Eklund L., El Hedri S., Ellis J., Emery S., Esmaili A., Esteve R., Evangelisti A., Feely M., Fedotov S., Feng J., Fernandez P., Fernández-Martinez E., Ferrario P., Ferrazzi,B., Feusels T., Finch A., Finley C., Fiorentini A., Fiorillo G., Fitton M., Frankiewicz K., Friend M., Fujii Y., Fukuda Y., Galinski G., Gao J., Garde C., Garfagnini A., Garode S., Gialanella L., Giganti C., Gomez-Cadenas J.J., Gonin M., González-Nuevo J., Gorin A., Gornea R., Gousy-Leblanc V. Gramegna F. Grassi M. Grella G. Guigue M. Gumplinger P. Hadley D.R. Harada M., Hartfiel B., Hartz M., Hassani S., Hastings N.C., Hayato Y., Hernando-Morata J.A., Herrero V., Hill J., Hiraide K., Hirota S., Holin A., Horiuchi S., Hoshina K., Hultqvist K., Iacob F., Ichikawa A.K., Idrissi Ibnsalih W., Iijima T., Ikeda M., Inomoto M., Inoue K., Insler J., Ioannisian A., Ishida T., Ishidoshiro K., Ishino H., Ishitsuka M., Ito H., Ito S., Itow Y., Iwamoto K., Izmaylov A., Izumi N., Izumiyama S., Jakkapu M., Jamieson B., Jang H.I., Jang J.S., Jenkins S.J., Jeon S.H., Jiang M., Jo H.S., Jonsson P., Joo K.K., Kajita T., Kakuno H., Kameda J., Kano Y., Kalaczynski P., Karlen D., Kasperek J., Kataoka Y., Kato A., Katori T., Kazarian N., Kearns E., Khabibullin M., Khotjantsev A., Kikawa T., Kekic M., Kim J.H., Kim J.Y., Kim S.B., Kim S.Y., King S., Kinoshita T., Kisiel Jan, Klekotko A., Kobayashi T., Koch L., Koga M., Koerich L., Kolev N., Konaka A., Kormos L.L., Koshio Y., Korzenev A., Kotsar Y., Kouzakov K.A., Kowalik K.L., Kravchuk L., Kryukov A.P., Kudenko Y., Kumita T., Kurjata R., Kutter T., Kuze M., Kwak K., La Commara M., Labarga L., Lagoda J., Lamers James J., Lamoureux M., Laveder M., Lavitola L., Lawe M., Learned J.G., Lee J., Leitner R., Lezaun V., Lim I.T., Lindner T., Litchfield R.P., Long K.R., Longhin A., Loverre P., Lu X., Ludovici L., Maekawa Y., Magaletti L., Magar K., Mahn K., Makida Y., Malek M., Malinský M., Marchi T., Maret L., Mariani C., Marinelli A., Martens K., Marti L., Martin J.F. Martin D., Marzec J., Matsubara T., Matsumoto R., Matsuno S., Matusiak M., Mazzucato E., McCarthy M., McCauley N., McElwee J., McGrew C., Mefodiev A., Medhi A., Mehta P., Mellet L., Menjo H., Mermod P., Metelko C., Mezzetto M., Migenda J., Migliozzi P., Mijakowski P., Miki S., Miller E.W., Minakata H., Minamino A., Mine S., Mineev O., Mitra A., Miura M., Moharana R., Mollo C.M., Mondal T., Mongelli M., Monrabal F., Moon D.H., Moon C.S., Mora F.J., Moriyama S., Mueller Th.A., Munteanu L., Murase K., Nagao Y., Nakadaira T., Nakagiri K., Nakahata M., Nakai S., Nakajima Y., Nakamura K., Nakamura KI., Nakamura H., Nakano Y., Nakaya T., Nakayama S., Nakayoshi K., Nascimento Machado L., Naseby C.E.R., Navarro-Garcia B., Needham M., Nicholls T., Niewczas K., Nishimura Y., Noah E., Nova F., Nugent J.C., Nunokawa H., Obrebski W., Ochoa-Ricoux J.P., O’Connor E., Ogawa N., Ogitsu T., Ohta K., Okamoto K., O’Keeffe H.M., Okumura K., Onishchuk Y., Orozco-Luna F., Oshlianskyi A., Ospina N., Ostrowski M., O’Sullivan E., O’Sullivan L., Ovsiannikova T., Oyama Y., Ozaki H., Pac M.Y., Paganini P., Palladino V., Paolone V., Pari M., Parsa S., Pasternak J., Pastore C., Pastuszak G., Patel D.A., Pavin M., Payne D., Peña-Garay C., Pidcott C., Pinzon Guerra E., Playfer S., Pointon B.W., Popov A., Popov B., Porwit Kamil, Posiadala-Zezula M., Poutissou J.M., Pozimski J., Pronost G., Prouse N.W., Przewlocki P., Quilain B., Quiroga A.A., Radicioni E., Radics B., Rajda P.J., Renner J., Rescigno M., Retiere F., Ricciardi G., Riccio C., Richards B., Rondio E., Rose H.J., Roskovec B., Roth S., Rott C., Rountree S.D., Rubbia A., Ruggeri A.C., Ruggles C., Russo S., Rychter A., Ryu D., Sakashita K., Samani S., Sánchez F., Sánchez M.L., Sanchez M.C., Sano S., Santos J.D., Santucci G., Sarmah P., Sashima I., Sato K., Scott M., Seiya Y., Sekiguchi T., Sekiya H., Seo J.W., Seo S.H., Sgalaberna D., Shaikhiev A., Shan Z., Shaykina A., Shimizu I., Shin C.D., Shinoki M., Shiozawa M., Sinnis G., Skrobova N., Skwarczynski K., Smy M.B., Sobczyk J., Sobel H.W., Soler F. J. P., Sonoda Y., Spina R., Spisso B., Spradlin B., Stankevich K.L., Stawarz L., Stellacci S.M., Stopa K., Studenikin A.I., Suárez Gómez S.L., Suganuma T., Suvorov S., Suwa Y., Suzuki A.T., Suzuki S.Y., Suzuki Y., Svirida D., Svoboda R., Taani M., Tada M., Takeda A., Takemoto Y., Takenaka A., Taketa A., Takeuchi Y., Takhistov V., Tanaka H., Tanaka H.A., Tanaka H.I., Tanaka M., Tashiro T., Thiesse M., Thompson L.F., Toledo J., Tomatani-Sánchez A.K., Tortone G., Tsui K.M., Tsukamoto T., Tzanov M., Uchida Y., Vagins M.R., Valder S., Valentino V., Vasseur G., Vijayvargi A., Vilela C., Vinning W. G. S., Vivolo D., Vladisavljevic T., Vogelaar R.B., Vyalkov M.M., Wachala T., Walker J., Wark D., Wascko M.O., Wendell R.A., Wilkes R.J., Wilking M.J., Wilson M.R., Wronka S., Xia J., Xie Z., Xin T., Yamaguchi Y., Yamamoto K., Yanagisawa C., Yano T., Yen S., Yershov N., Yeum D.N., Yokoyama M., Yonenaga M., Yoo J., Yu I., Yu M., Zakrzewski T., Zaldivar B., Zalipska J., Zaremba K., Zarnecki G., Ziembicki M., Zietara K., Zito M., Zsoldos S., Core-collapse supernovae are among the most magnificent events in the observable universe. They produce many of the chemical elements necessary for life to exist and their remnants-neutron stars and black holes-are interesting astrophysical objects in their own right. However, despite millennia of observations and almost a century of astrophysical study, the explosion mechanism of core-collapse supernovae is not yet well understood. Hyper-Kamiokande is a next-generation neutrino detector that will be able to observe the neutrino flux from the next galactic core-collapse supernova in unprecedented detail. We focus on the first 500 ms of the neutrino burst, corresponding to the accretion phase, and use a newly-developed, high-precision supernova event generator to simulate Hyper-Kamiokandeʼs response to five different supernova models. We show that Hyper-Kamiokande will be able to distinguish between these models with high accuracy for a supernova at a distance of up to 100 kpc. Once the next galactic supernova happens, this ability will be a powerful tool for guiding simulations toward a precise reproduction of the explosion mechanism observed in nature.
Published: 2022

10. National trends in prescription drug expenditures and projections for 2021

Author: James M. Hoffman, Matthew H Rim, Katie J. Suda, Michelle D. Wiest, John S. Clark, Mina Tadrous, Linda M. Matusiak, Glen T. Schumock, Sandra Cuellar, and Eric M Tichy
Subjects: Drug, Prescription Drugs, Prescription drug, Databases, Factual, clinics, media_common.quotation_subject, Specialty, Pharmacy, Legislation, 030204 cardiovascular system & hematology, Drug Costs, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Pandemic, prescription expenditures, Drugs, Generic, Humans, Medicine, Economics, Pharmaceutical, 030212 general & internal medicine, Biosimilar Pharmaceuticals, Health policy, media_common, Pharmacology, business.industry, Health Policy, Special Feature, COVID-19, Biosimilar, United States, COVID-19 Drug Treatment, AcademicSubjects/MED00410, Health Expenditures, hospitals, business
Abstract: Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Published: 2021

11. Positron accumulation in the GBAR experiment

Author: P. Blumer, M. Charlton, M. Chung, P. Cladé, P. Comini, P. Crivelli, O. Dalkarov, P. Debu, L. Dodd, A. Douillet, S. Guellati, P.-A. Hervieux, L. Hilico, A. Husson, P. Indelicato, G. Janka, S. Jonsell, J.-P. Karr, B.H. Kim, E.S. Kim, S.K. Kim, Y. Ko, T. Kosinski, N. Kuroda, B.M. Latacz, B. Lee, H. Lee, J. Lee, A.M.M. Leite, K. Lévêque, E. Lim, L. Liszkay, P. Lotrus, D. Lunney, G. Manfredi, B. Mansoulié, M. Matusiak, G. Mornacchi, V. Nesvizhevsky, F. Nez, S. Niang, R. Nishi, B. Ohayon, K. Park, N. Paul, P. Pérez, S. Procureur, B. Radics, C. Regenfus, J.-M. Reymond, S. Reynaud, J.-Y. Roussé, O. Rousselle, A. Rubbia, J. Rzadkiewicz, Y. Sacquin, F. Schmidt-Kaler, M. Staszczak, K. Szymczyk, T. Tanaka, B. Tuchming, B. Vallage, A. Voronin, D.P. van der Werf, S. Wolf, D. Won, S. Wronka, Y. Yamazaki, K.H. Yoo, P. Yzombard, C.J. Baker, Department of Physics [ETH Zürich] (D-PHYS), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Swansea University, Ulsan National Institute of Science and Technology (UNIST), Laboratoire Kastler Brossel (LKB [Collège de France]), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Université d'Évry-Val-d'Essonne (UEVE), Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Stockholm University, Institute for Basic Science [Daejeon] (IBS), Seoul National University [Seoul] (SNU), Korea University [Seoul], Narodowe Centrum Badań Jądrowych (NCBJ), The University of Tokyo (UTokyo), Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), European Organization for Nuclear Research (CERN), Institut Laue-Langevin (ILL), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), and GBAR
Subjects: Nuclear and High Energy Physics, Accumulator, Antimatter, Positron, Penning trap, Other Fields of Physics, FOS: Physical sciences, Physics - Plasma Physics, [PHYS.PHYS.PHYS-GEN-PH]Physics [physics]/Physics [physics]/General Physics [physics.gen-ph], Plasma Physics (physics.plasm-ph), electron: linear accelerator, positron: capture, gravitation, gas, physics.plasm-ph, Physics::Accelerator Physics, Physics::Atomic Physics, Instrumentation, Antihydrogen, antihydrogen: ion, performance
Abstract: We present a description of the GBAR positron (e+) trapping apparatus, which consists of a three stage Buffer Gas Trap (BGT) followed by a High Field Penning Trap (HFT), and discuss its performance. The overall goal of the GBAR experiment is to measure the acceleration of the neutral antihydrogen (H¯) atom in the terrestrial gravitational field by neutralising a positive antihydrogen ion (H¯+), which has been cooled to a low temperature, and observing the subsequent H¯ annihilation following free fall. To produce one H¯+ ion, about 1010 positrons, efficiently converted into positronium (Ps), together with about 107 antiprotons (p¯), are required. The positrons, produced from an electron linac-based system, are accumulated first in the BGT whereafter they are stacked in the ultra-high vacuum HFT, where we have been able to trap 1.4(2) × 109 positrons in 1100 s. We present a description of the GBAR positron (e+) trapping apparatus, which consists of a three stage Buffer Gas Trap (BGT) followed by a High Field Penning Trap (HFT), and discuss its performance. The overall goal of the GBAR experiment is to measure the acceleration of the neutral antihydrogen (H) atom in the terrestrial gravitational field by neutralising a positive antihydrogen ion (H+), which has been cooled to a low temperature, and observing the subsequent H annihilation following free fall. To produce one H+ ion, about 10^10 positrons, efficiently converted into positronium (Ps), together with about 10^7 antiprotons (p), are required. The positrons, produced from an electron linac-based system, are accumulated first in the BGT whereafter they are stacked in the ultra-high vacuum HFT, where we have been able to trap 1.4(2) x 10^9 positrons in 1100 seconds.
Published: 2022

12. Microbiological Causes Of Defects In Fetal Development And Miscarriage

Author: Dominik M. Matusiak
Subjects: TORCH, Microbiology (medical), medicine.medical_specialty, Fetus, business.industry, Obstetrics, lcsh:QR1-502, fetopathies, food and beverages, miscarriage / abortion, medicine.disease, Microbiology, lcsh:Microbiology, Miscarriage, birth defects, embryonic structures, medicine, business
Abstract: During pregnancy many agents can be teratogenic i.e. can be dangerous for embryo or fetus and cause differentiated adverse effects. Teratogenic agents include substances (e.g. many pharmaceuticals, mycotoxins – e.g. aflatoxins and ochratoxin A), radiation (e.g. X/RTG, γ) and infectious agents. The latter include bacteria (e.g. Listeria monocytogenes, Treponema pallidum), protozoa (e.g. Toxoplasma gondii) and viruses (e.g. ZIKV, parvovirus B19, herpesviruses: CMV, HSV, VZV). Quite a few pathogens can be vertically transmitted, i.e. through placenta (poorly understood mechanism), but not all are typical teratogenic agents (TORCH group). Infection during gestation can be oligosymptomatic or asymptomatic for the mother, nevertheless can also be fatal for the child, causing among others IUGR, SNHL, malformation (e.g. microcephaly, limb defects), abortion. Some (but not all) of these abnormalities can be non-invasively diagnosed by ultrasonography (USG) and prevented by vaccination (in case of the rubella and varicella). In some countries routine serological diagnostics for selected pathogens are performed during pregnancy. Generally transplacental transmission occur mostly during initial (primary) infection and are most dangerous during the first and second trimester (intensive morphogenesis and organogenesis). Conversely chance of fetus infection usually increases with time and is highest in the third trimester. 1. Introduction. 2. Placenta. 3. Preterm delivery and vaginosis. 4. TORCH group. 5. Teratogenic microorganisms and viruses. 5.1. Bacteria. 5.2. Protozoa. 5.3. Viruses. 6. Mycotoxins. 6.1. Description of selected mycotoxins. 7. Summary
Published: 2020

13. Accumulation of positrons from a LINAC based source

Author: Young Ju Ko, P.-P. Crépin, N. Paul, JJ Choi, André Rubbia, Jaison Lee, Paul-Antoine Hervieux, P. Debu, P. Comini, M. Staszczak, K.H. Park, P Froehlich, D. P. van der Werf, SK Kim, O. D. Dalkarov, Bruno Mansoulie, D. Won, Jean-Philippe Karr, G Janka, M. Matusiak, Laszlo Liszkay, G Mornacchi, Serge Reynaud, B. Tuchming, C. J. Baker, Laurent Hilico, A. Douillet, F. Nez, J.-Y. Roussé, S. Niang, R. Nishi, D. Lunney, Sebastian Wolf, Ferdinand Schmidt-Kaler, Alexei Voronin, J Gafriller, Moses Chung, Yasunori Yamazaki, Paul Indelicato, C. Regenfus, T. Kosinski, J. Rzadkiewicz, S. Wronka, S. Guellati, L. Dodd, Pierre Cladé, A. Welker, B. Latacz, A. Husson, M. Charlton, A Kleyheeg, Svante Jonsell, B. Vallage, ES Kim, Y. Sacquin, T Louvradoux, BH Kim, Naofumi Kuroda, Giovanni Manfredi, E. Lim, S. Nourbaksh, H Lee, Valery Nesvizhevsky, K.-H. Yoo, K. Lévêque, P. Perez, Johannes Heinrich, B. Radics, Amm Leite, Paolo Crivelli, Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Swansea University, Seoul National University [Seoul] (SNU), Ulsan National Institute of Science and Technology (UNIST), Laboratoire Kastler Brossel (LKB (Jussieu)), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institute for Particle Physics and Astrophysics [ETH Zürich] (IPA), Department of Physics [ETH Zürich] (D-PHYS), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich)- Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Laboratoire Kastler Brossel (LKB [Collège de France]), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), P. N. Lebedev Physical Institute of the Russian Academy of Sciences [Moscow] (LPI RAS), Russian Academy of Sciences [Moscow] (RAS), Université d'Évry-Val-d'Essonne (UEVE), Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Centre de Sciences Nucléaires et de Sciences de la Matière (CSNSM), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), National Centre for Nuclear Research [Otwock], Narodowe Centrum Badań Jądrowych (NCBJ), Johannes Gutenberg - Universität Mainz (JGU), CERN [Genève], RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Département de Physique des Particules (ex SPP) (DPP), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Université Pierre et Marie Curie - Paris 6 (UPMC)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Department of Physics [Umeå], Umeå University, National Center for Nuclear Research (NCBJ), Centre for Water Research (CWR), The University of Western Australia (UWA), iMagX/MIRO, Université Catholique de Louvain = Catholic University of Louvain (UCL), Institut Laue-Langevin (ILL), ILL, Soltan Institute for Nuclear Studies, Institut für Quanteninformationsverarbeitung, Universität Ulm - Ulm University [Ulm, Allemagne], Lomonosov Moscow State University (MSU), Max-Planck-Institut für Astronomie (MPIA), Max-Planck-Gesellschaft, and Lancaster University
Subjects: 010302 applied physics, Physics, Measure (physics), General Physics and Astronomy, 02 engineering and technology, 021001 nanoscience & nanotechnology, Gravitational acceleration, 01 natural sciences, Linear particle accelerator, Positronium, Nuclear physics, Positron, Positron plasma, Positron accumulation, Antimatter, Penning-Malmberg trap, Greaves-Surko trap, GBAR, [PHYS.QPHY]Physics [physics]/Quantum Physics [quant-ph], Antiproton, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Physics::Accelerator Physics, Physics::Atomic Physics, 0210 nano-technology, Antihydrogen, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; The GBAR experiment aims to measure the gravitational acceleration of antihydrogen H̅. It will use H̅+ ions formed by the interaction of antiprotons with a dense positronium cloud, which will require about 1010 positrons to produce one H̅+. We present the first results on the positron accumulation, reaching 3.8±0.4×108 e+ collected in 560 s.
Published: 2020

14. A pulsed high-voltage decelerator system to deliver low-energy antiprotons

Author: Valery Nesvizhevsky, K.-H. Yoo, J.-M. Reymond, P. Comini, B. Latacz, F. Nez, Alexei Voronin, Laurent Hilico, L. Dodd, P.-P. Crépin, M. Staszczak, B.H. Kim, Giuseppe Mornacchi, Jean-Philippe Karr, A. M. M. Leite, G. Janka, N. Garroum, S. Procureur, J.J. Choi, J.-Y. Roussé, J. Rzadkiewicz, Paul Indelicato, Hyo-Suk Lee, Pierre Cladé, M. Matusiak, B. Tuchming, T. Kosinski, P. Debu, Yasunori Yamazaki, Sun-Whe Kim, Eun-San Kim, A. Welker, Paolo Crivelli, M. Charlton, M. Chung, A. Husson, S. Wronka, S. Wolf, B. Vallage, O. D. Dalkarov, Y. Sacquin, C. Regenfus, S. Guellati-Khélifa, Naofumi Kuroda, R. Nishi, Serge Reynaud, Jaison Lee, S. Nourbaksh, Young Ju Ko, A. Douillet, Paul-Antoine Hervieux, D. Lunney, N. Paul, K. Lévêque, Giovanni Manfredi, P. Lotrus, P. Pérez, O. Rousselle, Bruno Mansoulie, E. Lim, Laszlo Liszkay, Svante Jonsell, K.H. Park, S. Niang, Ferdinand Schmidt-Kaler, André Rubbia, D. P. van der Werf, D. Won, B. Radics, Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Seoul National University [Seoul] (SNU), CERN [Genève], Swansea University, Ulsan National Institute of Science and Technology (UNIST), Laboratoire Kastler Brossel (LKB [Collège de France]), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institute for Particle Physics and Astrophysics [ETH Zürich] (IPA), Department of Physics [ETH Zürich] (D-PHYS), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich)- Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), P. N. Lebedev Physical Institute of the Russian Academy of Sciences [Moscow] (LPI RAS), Russian Academy of Sciences [Moscow] (RAS), Université d'Évry-Val-d'Essonne (UEVE), Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Stockholm University, Korea University [Seoul], Institute for Basic Science [Daejeon] (IBS), National Centre for Nuclear Research [Otwock], Narodowe Centrum Badań Jądrowych (NCBJ), The University of Tokyo (UTokyo), Institut Laue-Langevin (ILL), Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), RIKEN - Institute of Physical and Chemical Research [Japon] (RIKEN), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Université de Strasbourg (UNISTRA)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), ILL, and Johannes Gutenberg - Universität Mainz (JGU)
Subjects: Nuclear and High Energy Physics, Drift tube, General Relativity, Ion-optic simulations, CERN Lab, drift tube, Astrophysics::High Energy Astrophysical Phenomena, [PHYS.PHYS.PHYS-ACC-PH]Physics [physics]/Physics [physics]/Accelerator Physics [physics.acc-ph], Charged-particle optics, fabrication, 7. Clean energy, 01 natural sciences, anti-p: deceleration, law.invention, Nuclear physics, law, 0103 physical sciences, synchrotron, Physics::Atomic Physics, 010306 general physics, Antihydrogen, numerical calculations, Instrumentation, accelerator: design, Physics, antihydrogen, Large Hadron Collider, 010308 nuclear & particles physics, High voltage, Charged particle, Synchrotron, [PHYS.PHYS.PHYS-GEN-PH]Physics [physics]/Physics [physics]/General Physics [physics.gen-ph], Pulse (physics), beam optics, Antiproton, Physics::Accelerator Physics
Abstract: International audience; The GBAR (Gravitational Behavior of Antihydrogen at Rest) experiment at CERN requires efficient deceleration of 100 keV antiprotons provided by the new ELENA synchrotron ring to synthesize antihydrogen. This is accomplished using electrostatic deceleration optics and a drift tube that is designed to switch from -99 kV to ground when the antiproton bunch is inside – essentially a charged particle “elevator” – producing a 1 keV pulse. We describe the simulation, design, construction and successful testing of the decelerator device at -92 kV on-line with antiprotons from ELENA.
Published: 2021

15. National trends in prescription drug expenditures and projections for 2020

Author: John S. Clark, Katie J. Suda, Matthew H Rim, Michelle D. Wiest, JoAnn Stubbings, Sandra Cuellar, Glen T. Schumock, Linda M. Matusiak, Robert J. Hunkler, Mina Tadrous, James M. Hoffman, Lee C. Vermeulen, and Eric M Tichy
Subjects: Drug, Prescription drug, Prescription Drugs, Databases, Factual, media_common.quotation_subject, Specialty, New Drug Approvals, Legislation, 030226 pharmacology & pharmacy, Ambulatory Care Facilities, Drug Costs, 03 medical and health sciences, 0302 clinical medicine, Environmental health, medicine, Humans, 030212 general & internal medicine, National trends, Economics, Hospital, media_common, Pharmacology, Health Policy, Biosimilar, United States, Editorial, AcademicSubjects/MED00410, Apixaban, Business, medicine.drug
Abstract: Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2020 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2020 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for specialty drugs, biosimilars, and diabetes medications. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2020 were based on a combination of quantitative analyses and expert opinion. Results In 2019, overall US pharmaceutical expenditures grew 5.4% compared to 2018, for a total of $507.9 billion. This increase was driven to similar degrees by prices, utilization, and new drugs. Adalimumab was the top drug in US expenditures in 2019, followed by apixaban and insulin glargine. Drug expenditures were $36.9 billion (a 1.5% increase from 2018) and $90.3 billion (an 11.8% increase from 2018) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals growth was driven by new products and price increases. Several new drugs that will likely influence spending are expected to be approved in 2020. Specialty and cancer drugs will continue to drive expenditures. Conclusion For 2020 we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 9.0% to 11.0% and 2.0% to 4.0%, respectively, compared to 2019. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Published: 2020

16. Spending on Antineoplastic Agents in the United States, 2011 to 2016

Author: Samuel J Hong, Edward C. Li, Linda M. Matusiak, and Glen T. Schumock
Subjects: 03 medical and health sciences, 0302 clinical medicine, Oncology, Oncology (nursing), business.industry, 030220 oncology & carcinogenesis, Health Policy, Environmental health, Cancer drugs, Health care, Medicine, 030212 general & internal medicine, business
Abstract: Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of January 1, 2011, to December 31, 2016. Actual expenditures were totaled by health care sector and calendar year, then adjusted for medical-cost inflation to 2016 dollars. Growth was calculated as the percentage increase from the previous year. Results: Total expenditures of antineoplastic agents across all channels grew from $26.8 billion in 2011 to $42.1 billion in 2016. Antineoplastic spending increased 12.2% in 2016 (compared with the previous year), followed by 15.6% in 2015, 13.4% in 2014, 6.3% in 2013, and 0.4% in 2012. Throughout the study period, 96.5% of total antineoplastic expenditures occurred within clinics, mail-order pharmacies, nonfederal hospitals, and retail pharmacies. Conclusion: Antineoplastic expenditures are expected to increase because of continuing development and approval of costly targeted cancer therapies. Cost containment and utilization management strategies must be balanced so as not to restrict access or disrupt innovation. Future policies should focus on ensuring safe and appropriate use of antineoplastics while balancing long-term drug costs.
Published: 2018

17. National trends in prescription drug expenditures and projections for 2017

Author: Robert J. Hunkler, Katie J. Suda, Glen T. Schumock, JoAnn Stubbings, Michelle D. Wiest, Linda M. Matusiak, Edward C. Li, and Lee C. Vermeulen
Subjects: Drug, Drug Utilization, medicine.medical_specialty, Prescription Drugs, Prescription drug, Databases, Factual, media_common.quotation_subject, New Drug Approvals, Pharmacy, 030204 cardiovascular system & hematology, Drug Costs, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, 030212 general & internal medicine, National trends, Medical prescription, media_common, Pharmacology, business.industry, Health Policy, United States, Pharmaceutical Services, Expert opinion, Family medicine, Health Expenditures, business
Abstract: Purpose Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2017 in nonfederal hospitals, clinics, and overall (all sectors). Methods Drug expenditure data through calendar year 2016 were obtained from the QuintilesIMS National Sales Perspectives database and analyzed. Other factors that may influence drug spending in hospitals and clinics in 2017, including new drug approvals and patent expirations, were also reviewed. Expenditure projections for 2017 for nonfederal hospitals, clinics, and overall (all sectors) were made based on a combination of quantitative analyses and expert opinion. Results Total U.S. prescription sales in the 2016 calendar year were $448.2 billion, a 5.8% increase compared with 2015. More than half of the increase resulted from price hikes of existing drugs. Adalimumab was the top drug overall in 2016 expenditures ($13.6 billion); in clinics and nonfederal hospitals, infliximab was the top drug. Prescription expenditures in clinics and nonfederal hospitals totaled $63.7 billion (an 11.9% increase from 2015) and $34.5 billion (a 3.3% increase from 2015), respectively. In nonfederal hospitals and clinics, growth in spending was driven primarily by price increases of existing drugs and increased volume, respectively. Conclusion We project a 6.0–8.0% increase in total drug expenditures across all settings, an 11.0–13.0% increase in clinics, and a 3.0–5.0% increase in hospital drug spending in 2017. Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2017.
Published: 2017

18. Spending on Hepatitis C Antivirals in the United States, 2009-2015

Author: Katie J. Suda, Glen T. Schumock, Linda M. Matusiak, Robert J. Hunkler, and Drew J. Halbur
Subjects: medicine.medical_specialty, Time Factors, Cross-sectional study, 030204 cardiovascular system & hematology, Antiviral Agents, Drug Costs, Telaprevir, 03 medical and health sciences, 0302 clinical medicine, Health care, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Adverse effect, Retrospective Studies, Withholding Treatment, business.industry, Retrospective cohort study, Hepatitis C, medicine.disease, United States, Cross-Sectional Studies, Drug development, Health Expenditures, business, medicine.drug
Abstract: Study objective New hepatitis C virus (HCV) antivirals have been shown to be highly effective with minimal adverse effects, but they are costly. Little is known, however, about the impact of the new HCV antivirals on expenditures in the overall U.S. health care system or by health care sector. Thus the objective of this study was to describe HCV antiviral expenditures by agent, year, and health care sector. Design Retrospective cross-sectional study. Data source QuintilesIMS National Sales Perspectives database. Measurements and main results QuintilesIMS National Sales Perspectives data for the period of January 1, 2009, to December 31, 2015, were used to describe HCV antiviral expenditures. HCV antiviral expenditures grew each year from $78 million in 2009 to $18 billion in 2015, except during 2013 when spending on HCV drugs dropped by $684 million (41%) compared with 2012. Although most expenditures in 2009 and 2010 were for interferons, this shifted to telaprevir in 2011-2013 and sofosbuvir-containing regimens in 2014-2015. Mail service and community pharmacies were associated with most of the expenditures throughout the study period. Conclusion New HCV antivirals are driving the increased expenditures for this class. Decreased expenditures in 2013 may have been secondary to delaying HCV treatment until new therapies received approval from the U.S. Food and Drug Administration (termed "warehousing"). With continued drug development and approval of HCV therapies, expenditures are expected to continue to increase, barring actions by payers that may impede this trend. Medication policies guiding HCV treatment should focus on safety and efficacy while balancing the long-term costs of HCV.
Published: 2016

19. Development of a PbWO 4 detector for single-shot positron annihilation lifetime spectroscopy at the GBAR experiment

Author: Paolo Crivelli, JJ Choi, Jean-Philippe Karr, C. Regenfus, G Mornacchi, Y. Sacquin, BH Kim, Naofumi Kuroda, SK Kim, B. Radics, M. Staszczak, S. Nourbaksh, B. Vallage, Young Ju Ko, Sebastian Wolf, P. Comini, Bruno Mansoulie, P Froehlich, J. Rzadkiewicz, P.-P. Crépin, F. Nez, N. Paul, Pierre Cladé, Alexei Voronin, S. Guellati, L. Dodd, A. Husson, Giovanni Manfredi, Svante Jonsell, M. Matusiak, Paul Indelicato, Amm Leite, Serge Reynaud, T. Kosinski, O. D. Dalkarov, T Louvradoux, Moses Chung, S. Wronka, A. Welker, Laurent Hilico, R. Nishi, E. Lim, K.H. Park, H Lee, Laszlo Liszkay, Jaison Lee, Paul-Antoine Hervieux, P. Debu, ES Kim, P. Lotrus, André Rubbia, K. Lévêque, D. P. van der Werf, D. Won, J.-Y. Roussé, S. Niang, Ferdinand Schmidt-Kaler, P. Perez, A Douillet, B. Latacz, D. Lunney, G. Janka, B. Tuchming, Yasunori Yamazaki, Valery Nesvizhevsky, K.-H. Yoo, Johannes Heinrich, Laboratoire Kastler Brossel (LKB (Jussieu)), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Centre de Sciences Nucléaires et de Sciences de la Matière (CSNSM), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), European Organization for Nuclear Research (CERN), Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université de Strasbourg (UNISTRA)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département de Physique des Particules (ex SPP) (DPP), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology in Zürich [Zürich] (ETH Zürich), Laboratoire Kastler Brossel (LKB [Collège de France]), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et nanosciences d'Alsace, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Université de Strasbourg (UNISTRA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Department of Physics [Umeå], Umeå University, Université d'Évry-Val-d'Essonne (UEVE), National Center for Nuclear Research (NCBJ), Centre for Water Research (CWR), The University of Western Australia (UWA), iMagX/MIRO, Université Catholique de Louvain (UCL), Institut Laue-Langevin (ILL), ILL, Girardel - Laboratoire Leïdi (Leïdi), Université Gaston Berger de Saint-Louis Sénégal (UGB), Soltan Institute for Nuclear Studies, Institut für Quanteninformationsverarbeitung, Universität Ulm - Ulm University [Ulm, Allemagne], Lomonosov Moscow State University (MSU), Max-Planck-Institut für Astronomie (MPIA), Max-Planck-Gesellschaft, and Lancaster University
Subjects: Physics, Physics::Instrumentation and Detectors, [PHYS.PHYS.PHYS-ACC-PH]Physics [physics]/Physics [physics]/Accelerator Physics [physics.acc-ph], Detector, Measure (physics), General Physics and Astronomy, 7. Clean energy, Ion, Nuclear physics, Cross section (physics), [PHYS.QPHY]Physics [physics]/Quantum Physics [quant-ph], PACS: 78.70.Bj, 41.75.Fr, 36.10.Dr, Yield (chemistry), Reflection (physics), [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], Antihydrogen, Spectroscopy, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; We have developed a PbWO 4 (PWO) detector with a large dynamic range to measure the intensity of a positron beam and the absolute density of the ortho-positronium (o-Ps) cloud it creates. A simulation study shows that a setup based on such detectors may be used to determine the angular distribution of the emission and reflection of o-Ps to reduce part of the uncertainties of the measurement. These will allow to improve the precision in the measurement of the cross section for the (anti) hydrogen formation by (anti) proton-positronium charge exchange and to optimize the yield of antihydrogen ion which is an essential parameter in the GBAR experiment.
Published: 2019

20. National trends in prescription drug expenditures and projections for 2019

Author: Katie J. Suda, John S. Clark, JoAnn Stubbings, Matthew H Rim, James M. Hoffman, Sandra Cuellar, Mina Tadrous, Linda M. Matusiak, Eric M Tichy, Michelle D. Wiest, Robert J. Hunkler, Lee C. Vermeulen, and Glen T. Schumock
Subjects: Pharmacology, Drug Utilization, Prescription drug, Prescription Drugs, Databases, Factual, business.industry, Health Policy, Specialty, Pharmacy, 030204 cardiovascular system & hematology, Drug Costs, United States, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Humans, National level, 030212 general & internal medicine, National trends, Medical prescription, Health Expenditures, business, Moderate growth
Abstract: PurposeHistorical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2019 in nonfederal hospitals, clinics, and overall (all sectors).MethodsDrug expenditure data through calendar year 2018 were obtained from the IQVIA National Sales Perspectives database and analyzed. New drug approvals, patent expirations, and other factors that may influence drug spending in hospitals and clinics in 2019 were also reviewed. Expenditure projections for 2019 for nonfederal hospitals, clinics, and overall (all sectors) were made through a combination of quantitative analyses and expert opinion.ResultsU.S. prescription sales in calendar year 2018 totaled $476.2 billion, a 5.5% increase from 2017 spending. The top 3 drugs by expenditures were adalimumab ($19.1 billion), insulin glargine ($9.3 billion), and etanercept ($8.0 billion). Prescription expenditures in nonfederal hospitals totaled $35.8 billion, a 4.8% increase from 2017. Expenditures in clinics in 2018 increased by 13.0% to $80.5 billion. The increase in spending in nonfederal hospitals was largely driven by new products and increased utilization of existing products. The list of the top 25 drugs by expenditures in nonfederal hospitals and clinics was dominated by specialty drugs.ConclusionWe predict continued moderate growth of 4–6% in overall drug expenditures (across the entire U.S. market). We expect the clinic sector to continue to experience high (11–13%) growth in drug spending in 2019. Finally, for nonfederal hospitals we anticipate growth in the range of 3–5%. These estimates are at the national level. Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization’s anticipated spending in 2019.
Published: 2019

21. Positron production using a 9 MeV electron linac for the GBAR experiment

Author: B. Radics, Alexei Voronin, L. Dodd, S. Niang, Bruno Mansoulie, Ferdinand Schmidt-Kaler, Valery Nesvizhevsky, P.-P. Crépin, Paul Indelicato, A. Husson, K.-H. Yoo, T. Kosinski, B. Latacz, A. Welker, Eun-San Kim, P. Debu, Laszlo Liszkay, André Rubbia, J. Rzadkiewicz, R. Nishi, Pierre Cladé, D. Lunney, G. Janka, Y. Sacquin, Paolo Crivelli, D. P. van der Werf, O. Rousselle, Jaison Lee, J.-M. Rey, D. Won, B.H. Kim, Paul-Antoine Hervieux, Naofumi Kuroda, S. Wolf, P. Lotrus, E. Lim, P. Pérez, Giuseppe Mornacchi, Jean-Philippe Karr, O. D. Dalkarov, M. Charlton, C. Regenfus, S. Guellati-Khélifa, S. Nourbaksh, Serge Reynaud, A. Douillet, Svante Jonsell, J.-M. Reymond, S. K. Kim, F. Nez, J.-Y. Roussé, M. Staszczak, K.H. Park, Giovanni Manfredi, Hyo-Suk Lee, JJ Choi, Young Ju Ko, M. Matusiak, N. Paul, Laurent Hilico, Moses Chung, S. Wronka, B. Tuchming, Yasunori Yamazaki, K. Lévêque, B. Vallage, T Louvradoux, P. Comini, A. M. M. Leite, S. Procureur, Laboratoire Kastler Brossel (LKB [Collège de France]), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Collège de France (CdF (institution)), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS), Université de Strasbourg (UNISTRA)-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Centre de Sciences Nucléaires et de Sciences de la Matière (CSNSM), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut Laue-Langevin (ILL), ILL, Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF (institution))-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), and Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)
Subjects: safety, Antimatter, Nuclear and High Energy Physics, CERN Lab, Physics - Instrumentation and Detectors, tungsten, Positron, Astrophysics::High Energy Astrophysical Phenomena, FOS: Physical sciences, Electron, 01 natural sciences, 7. Clean energy, Linear particle accelerator, positron: particle source, 010305 fluids & plasmas, electron: pair production, Nuclear physics, electron: linear accelerator, Linear accelerator, Antihydrogen, Gravitation, 0103 physical sciences, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], Detectors and Experimental Techniques, Nuclear Experiment, 010306 general physics, physics.ins-det, Instrumentation, energy: low, antihydrogen, Physics, Large Hadron Collider, gravitation 2, Instrumentation and Detectors (physics.ins-det), linear accelerator, Antiproton Decelerator, Pair production, radioactivity, gravitation: acceleration, Physics::Accelerator Physics, High Energy Physics::Experiment, performance, positron: yield
Abstract: For the GBAR (Gravitational Behaviour of Antihydrogen at Rest) experiment at CERN's Antiproton Decelerator (AD) facility we have constructed a source of slow positrons, which uses a low-energy electron linear accelerator (linac). The driver linac produces electrons of 9 MeV kinetic energy that create positrons from bremsstrahlung-induced pair production. Staying below 10 MeV ensures no persistent radioactive activation in the target zone and that the radiation level outside the biological shield is safe for public access. An annealed tungsten-mesh assembly placed directly behind the target acts as a positron moderator. The system produces $5\times10^7$ slow positrons per second, a performance demonstrating that a low-energy electron linac is a superior choice over positron-emitting radioactive sources for high positron flux., published in NIM A. 33 pages 9 figures
Published: 2021

22. Superconductivity and Ferromagnetism in La0.67Sr0.33MnO3/YBa2Cu3O7Nanosized Heterostructures

Author: M. Matusiak, Krzysztof Rogacki, P. Przyslupski, H. Lochmajer, and G. Urbanik
Subjects: Superconductivity, Materials science, Ferromagnetism, Condensed matter physics, 0103 physical sciences, General Physics and Astronomy, Heterojunction, 02 engineering and technology, 021001 nanoscience & nanotechnology, 010306 general physics, 0210 nano-technology, 01 natural sciences
Published: 2016

23. National trends in prescription drug expenditures and projections for 2016

Author: Robert J. Hunkler, Edward C. Li, Lee C. Vermeulen, Katie J. Suda, JoAnn Stubbings, Michelle D. Wiest, Linda M. Matusiak, and Glen T. Schumock
Subjects: Drug Utilization, Prescription Drugs, Prescription drug, Specialty, New Drug Approvals, Pharmacy, 030204 cardiovascular system & hematology, Ambulatory Care Facilities, Drug Costs, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Humans, Medicine, 030212 general & internal medicine, National trends, Economics, Hospital, Medical prescription, Drug Approval, Pharmacies, Pharmacology, business.industry, Health Policy, United States, Pharmaceutical Services, Health Expenditures, business, Combination drug
Abstract: Purpose Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2016 in nonfederal hospitals, clinics, and overall (all sectors). Methods Drug expenditure data through calendar year 2015 were obtained from the IMS Health National Sales Perspectives database and analyzed. Other factors that may influence drug spending in hospitals and clinics in 2016, including new drug approvals and patent expirations, were also reviewed. Expenditure projections for 2016 were based on a combination of quantitative analyses and expert opinion. Results Total U.S. prescription sales in the 2015 calendar year were $419.4 billion, which was 11.7% higher than sales in 2014. Prescription expenditures in clinics and nonfederal hospitals totaled $56.7 billion (a 15.9% increase) and $33.6 billion (a 10.7% increase), respectively, in 2015. In nonfederal hospitals, growth in spending was driven primarily by increased prices for existing drugs. The hepatitis C combination drug ledipasvir–sofosbuvir was the top drug overall in terms of 2015 expenditures ($14.3 billion); in both clinics and nonfederal hospitals, infliximab was the top drug. Individual drugs with the greatest increases in expenditures in 2015 were specialty agents and older generics; these agents are likely to continue to influence total spending in 2016. Conclusion We project an 11–13% increase in total drug expenditures overall in 2016, with a 15–17% increase in clinic spending and a 10–12% increase in hospital spending. Health-system pharmacy leaders should carefully examine local drug utilization patterns in projecting their own organization’s drug spending in 2016.
Published: 2016

24. National trends in prescription drug expenditures and projections for 2015

Author: Katie J. Suda, Lee C. Vermeulen, Linda M. Matusiak, Edward C. Li, Robert J. Hunkler, JoAnn Stubbings, Glen T. Schumock, and Michelle D. Wiest
Subjects: Pharmacology, Drug Utilization, medicine.medical_specialty, Prescription Drugs, Prescription drug, Sofosbuvir, business.industry, Health Policy, Specialty, Epoetin alfa, Pharmacy, Drug Costs, Hospitals, United States, Patents as Topic, Family medicine, Humans, Medicine, Health Expenditures, Medical prescription, business, Drug Approval, Pegfilgrastim, medicine.drug
Abstract: Purpose An analysis of trends in U.S. pharmaceutical spending is presented, including projections for drug expenditures in nonfederal hospital and clinic settings in 2015. Methods Prescription drug expenditure data through September 2014 were obtained from the IMS Health National Sales Perspectives database and were analyzed descriptively. Other factors that may influence prescription spending in hospitals and clinics in 2015, including new drug approvals and patent expirations, were analyzed. Expenditure projections were based on a combination of quantitative and qualitative analyses and expert opinion. Results Total prescription sales for the 12 months ending September 30, 2014, were $360.7 billion, 12.2% higher than during the previous 12 months. With $6.6 billion in expenditures in the first 9 months of 2014, sofosbuvir topped the overall list of drugs based on sales, followed by aripiprazole and insulin glargine. Pharmaceutical spending by clinics and nonfederal hospitals rose by 13.3% and 4.0%, respectively. For the first 9 months of 2014, the top drugs based on expenditures were infliximab, pegfilgrastim, and epoetin alfa in clinics and infliximab, rituximab, and pegfilgrastim in hospitals. Specialty drugs continued to constitute an increasing portion of drug expenditures and will contribute to higher expenditures in 2015. Conclusion Growth in U.S. prescription drug expenditures is expected to continue to increase in 2015. The projected increases in total drug expenditures are 7–9% across all settings, 12–14% in clinics, and 5–7% in hospitals. Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2015.
Published: 2015

25. National trends in prescription drug expenditures and projections for 2014

Author: Katie J. Suda, James M. Hoffman, Robert J. Hunkler, Edward C. Li, Linda M. Matusiak, Glen T. Schumock, and Lee C. Vermeulen
Subjects: Pharmacology, medicine.medical_specialty, Prescription Drugs, Prescription drug, business.industry, Health Policy, New Drug Approvals, Pharmacy, United States, Family medicine, Health care, Patient Protection and Affordable Care Act, medicine, Humans, National trends, Business, Health Expenditures, Medical prescription, Drug Approval, Pegfilgrastim, medicine.drug
Abstract: Purpose An analysis of trends in U.S. pharmaceutical spending is presented, including projections for drug expenditures in nonfederal hospital and clinic settings in 2014. Methods Trends in pharmaceutical expenditures and developments likely to influence future spending, including new drug approvals and patent expirations, were analyzed using data from the IMS Health National Sales Perspectives database. Projections were based on a combination of quantitative and qualitative analyses and expert opinion. Results Total prescription sales for the 12 months ending September 2013 were approximately $326 billion, 0.7% lower than sales during the previous 12 months; pharmaceutical spending by clinics and nonfederal hospitals grew by 4.5% and 1.8%, respectively. Vaccines were among the products driving large sales increases in clinic settings, with alteplase and pegfilgrastim topping the list of fast-growing drugs by hospital expenditures. Few new drug approvals anticipated in 2014 are expected to result in major expenditures by hospitals and clinics. Expansion of access to health care and other changes related to the Patient Protection and Affordable Care Act, as well as continued improvement in the U.S. economy, may drive growth in pharmaceutical spending over the next 12–24 months. Conclusion Growth in U.S. prescription drug expenditures is expected to rebound in 2014, with a projected 3–5% increase in total drug expenditures across all settings this year, including a 5–7% increase in clinic spending and a 1–3% increase in hospital spending. Health-system pharmacy leaders should carefully examine local drug-utilization patterns to determine their respective organization’s anticipated spending in 2014.
Published: 2014

26. Electron transport and magnetic properties of semimetallic LuAs

Author: Ryszard Wawryk, O.J. Żogał, M. Matusiak, and Zygmunt Henkie
Subjects: Condensed matter physics, Chemistry, Mechanical Engineering, Metals and Alloys, Analytical chemistry, Resonance, Knight shift, Residual resistivity, Magnetization, Mechanics of Materials, Electrical resistivity and conductivity, Hall effect, Seebeck coefficient, Materials Chemistry, Charge carrier
Abstract: Polycrystalline samples of LuAs with a residual resistivity ratio (RRR) between 2.52 and 3.38 were examined by: X-ray diffraction, magnetisation, resistivity, magnetoresistivity, Hall coefficient and thermoelectric power S(T), in addition to the nuclear magnetic resonance (NMR) of 75As and 175Lu nuclei. The density and mobility of carriers for the valence and conduction bands were determined for the RRR = 2.52 sample and used for the calculation of thermoelectric power, Sc(T). The value of Sc(T) fits well with that determined by experiment. The sample shows a charge imbalance with the number of electrons n, (holes, p) equal to 1.52 × 1020 (1.12 × 1020) e/cm3 at 4 K. This imbalance decreases with temperature, reversing after passing a minimum at ∼80 K and then increasing to n (p) = 9.4 × 1019 (1.42 × 1020) e/cm3 at 300 K. The 75As NMR Knight shift is found to be temperature independent and equal to 0.102% and the 175Lu NMR resonance frequency is shifted to higher values by ca. 0.011% with respect to that of LuSb. All data indicate that LuAs belongs to semimetals and the clearly observed 175Lu NMR multiquadrupolar echoes suggest the existence of defects in the cubic structure of the investigated samples.
Published: 2014

27. Wireless hydrogen pressure dosimeter for nuclear high dose monitoring

Author: M. Matusiak, J. Philippe, Hervé Aubert, P. Knapkiewicz, Jan Dziuban, I. Augustyniak, M. Olszacki, Patrick Pons, E. Debourg, Équipe MIcro et Nanosystèmes pour les Communications sans fil (LAAS-MINC), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Wroclaw University of Science and Technology, National Center for Nuclear Research [Warsaw] (NCBJ), National Center for Nuclear Research (NCBJ), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), and Université Fédérale Toulouse Midi-Pyrénées
Subjects: Materials science, Dosimeter, Hydrogen, Atmospheric pressure, business.industry, 010401 analytical chemistry, chemistry.chemical_element, 020206 networking & telecommunications, 02 engineering and technology, 01 natural sciences, Hermetic seal, 0104 chemical sciences, law.invention, [SPI]Engineering Sciences [physics], Resonator, Pressure measurement, chemistry, law, 0202 electrical engineering, electronic engineering, information engineering, Wireless, Optoelectronics, Irradiation, business
Abstract: International audience; This communication reports the very first experimental results on an original wireless, chipless and passive (battery-less) sensor for monitoring high doses of nuclear radiation. The micro-sensor combines a miniature hydrogen pressure dosimeter with a passive microwave resonator. The pressure response is derived from S11-parameter measurement using vacuum and atmospheric pressure conditions. After e-beam irradiation (20kGy) the resonant frequency shift of the resonator ranges between 0.12%/kGy and 0.42%/kGy while the hydrogen pressure inside the cavity varies from 20mbar/kGy to 90mbar/kGy. No significant frequency shift is observed when using sensors during 6 months. These results demonstrate that a good hydrogen hermetic seal was fabricated during the manufacturing process of the constitutive micro-cavity.
Published: 2016

28. Interplay Between Spin Density Wave and Superconductivity in '122' Iron Pnictides:57Fe Mössbauer Study

Author: Artur Błachowski, Zbigniew Bukowski, M. Matusiak, Jan Żukrowski, Krzysztof Ruebenbauer, and J. Karpinski
Subjects: Superconductivity, Crystal, Materials science, Dopant, Condensed matter physics, Component (thermodynamics), Condensed Matter::Superconductivity, Mössbauer spectroscopy, General Physics and Astronomy, Spin density wave, Mossbauer spectra, Single phase
Abstract: Iron-based superconductors Ba0.7Rb0.3Fe2As2 and CaFe1.92Co0.08As2 of the ‘122’ family have been investigated by means of the 14.41-keV Mossbauer transition in Fe versus temperature ranging from the room temperature till 4.2 K. A comparison is made with the previously investigated parent compounds BaFe2As2 and CaFe2As2. It has been found that Mossbauer spectra of these superconductors are composed of the magnetically split component due to development of spin density wave (SDW) and non-magnetic component surviving even at lowest temperatures. The latter component is responsible for superconductivity. Hence, the superconductivity occurs in the part of the sample despite the sample is single phase. This phenomenon is caused by the slight variation of the dopant concentration across the sample (crystal).
Published: 2012

29. Infrared dispersion of liquid Benzylidenemethylamine and o-Hydroxybenzylidenemethylamine

Author: Teresa Dziembowska, M. Pajdowska, W. Wrzeszcz, Jerzy P. Hawranek, and M. Matusiak-Kucharska
Subjects: Permittivity, Infrared, Chemistry, Organic Chemistry, Near-infrared spectroscopy, Analytical chemistry, Astrophysics::Cosmology and Extragalactic Astrophysics, Polarization (waves), Spectral line, Analytical Chemistry, Inorganic Chemistry, Polarizability, Intramolecular force, Refractive index, Astrophysics::Galaxy Astrophysics, Spectroscopy
Abstract: The spectra of the real and imaginary components of the complex refractive index were determined in the NIR and MIR regions for liquid Benzylidenemethylamine and intramolecularly hydrogen-bonded o-Hydroxybenzylidenemethylamine from transmission studies using a method, which takes into account the dispersion of the refractive index in the Visible range and requires integration over the entire NIR and MIR region. From these data the spectra of both components of the complex electric permittivity and complex polarizability of both liquids were determined in the Visible, Near Infrared, and Mid Infrared spectral regions (25,000–600 cm−1). The molar vibrational polarization related to various spectral ranges has been determined. The considerable contribution due to the formed intramolecular H-bonding has been evaluated and discussed.
Published: 2010

30. Projecting future drug expenditures—2010

Author: James M. Hoffman, Fred Doloresco, Nilay Shah, Linda M. Matusiak, Glen T. Schumock, Lee C. Vermeulen, and Robert J. Hunkler
Subjects: Pharmacology, Drug, Comparative Effectiveness Research, business.industry, Health Policy, media_common.quotation_subject, Comparative effectiveness research, Biosimilar, Drug Costs, United States, Pharmaceutical Preparations, Health Care Reform, Environmental health, Drugs, Generic, Humans, Medicine, Health care reform, Economics, Hospital, Health Expenditures, business, Drug Approval, Forecasting, Moderate growth, media_common
Abstract: Purpose Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed. Summary Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008. Conclusion In 2010, we project a 3–5% increase in drug expenditures in outpatient settings, a 6–8% increase in expenditures for clinic-administered drugs, and a 2–4% increase in hospital drug expenditures.
Published: 2010

31. Fischer synthesis of isomeric thienopyrrole LHRH antagonists

Author: Zbegniew M. Matusiak, Benedicte Delouvrie, Craig S. Harris, Christine Lambert-van der Brempt, Maryannick Lamorlette, Jean-Claude Arnould, Kevin Michael Foote, Christian Delvare, David M. Andrews, Annie Hamon, and Pascal Boutron
Subjects: chemistry.chemical_compound, Chemistry, Stereochemistry, Organic Chemistry, Drug Discovery, Thienopyrrole, Biochemistry, Thiophene derivatives, Pyrrole
Abstract: As part of a structure–activity exploration into LHRH antagonists, structures containing the thieno[2,3-b]pyrrole core were identified as potent antagonists. This letter describes the employment of the Fischer synthesis to access this thienopyrrole and isomeric final compounds.
Published: 2009

32. Projecting future drug expenditures—2009

Author: Robert J. Hunkler, James M. Hoffman, Sharon Blake, Nilay Shah, Glen T. Schumock, Fred Doloresco, Linda M. Matusiak, Patrick K. Martin, and Lee C. Vermeulen
Subjects: Pharmacology, Drug, Drug supply, business.industry, Health Policy, media_common.quotation_subject, Medicare Part D, Pharmacy, Drug Costs, United States, Pharmaceutical Preparations, Environmental health, Drugs, Generic, Humans, Medicine, Economics, Hospital, Health Expenditures, business, Drug Approval, Forecasting, media_common, Moderate growth
Abstract: Purpose. Drug expenditure trends in 2007 and 2008, projected drug expenditures for 2009, and factors likely to influence drug expenditures are discussed. Summary. Various factors are likely to influence drug expenditures in 2009, including drugs in development, the diffusion of new drugs, drug safety concerns, generic drugs, Medicare Part D, and changes in the drug supply chain. The increasing availability of important generic drugs and drug safety concerns continue to moderate growth in drug expenditures. The drug supply chain remains dynamic and may influence drug expenditures, particularly in specialized therapeutic areas. Initial data suggest that the Medicare Part D benefit has influenced drug expenditures, but the ultimate impact of the benefit on drug expenditures remains unclear. From 2006 to 2007, total U.S. drug expenditures increased by 4.0%, with total spending rising from $276 billion to $287 billion. Drug expenditures in clinics continue to grow more rapidly than in other settings, with a 9.9% increase from 2006 to 2007. Hospital drug expenditures increased at a moderate rate of only 1.6% from 2006 to 2007; through the first nine months of 2008, hospital drug expenditures increased by only 2.8% compared with the same period in 2007. Conclusion. In 2009, we project a 0–2% increase in drug expenditures in outpatient settings, a 1–3% increase in expenditures for clinic-administered drugs, and a 1–3% increase in hospital drug expenditures.
Published: 2009

33. Accuracy of annual prescription drug expenditure forecasts in AJHP

Author: Katie J. Suda, Linda M. Matusiak, Edward C. Li, James M. Hoffman, Patricia L. Hartke, Nilay Shah, Lee C. Vermeulen, Glen T. Schumock, Fred Doloresco, and Robert J. Hunkler
Subjects: Societies, Pharmaceutical, Prescription drug, Prescription Drugs, education, Mean absolute error, Centers for Medicare and Medicaid Services, U.S, Article, Prescription Fee, Statistics, Medicine, Humans, Medical prescription, health care economics and organizations, Pharmacology, business.industry, Health Policy, Prescription Fees, Reproducibility of Results, Percentage point, social sciences, United States, population characteristics, business, Pharmacy Service, Hospital, Medicaid, Forecasting
Abstract: Purpose The accuracy of the forecasts of drug expenditures in nonfederal hospitals and clinics published annually in the American Journal of Health-System Pharmacy (AJHP) relative to the accuracy of forecasts produced by the Centers for Medicare and Medicaid Services (CMS) was evaluated. Methods AJHP -published forecasts of drug expenditure growth for nonfederal hospitals (for the years 2003 through 2013) and clinics (for the years 2004 through 2013) were compared with data on actual growth. Data on actual and projected growth published by CMS were analyzed for the years 2003 through 2012. The mean absolute error and directional accuracy of the forecasts published in AJHP for nonfederal hospitals and clinics and the CMS forecasts were determined and compared. Results Actual spending growth was within the range of the forecast published in AJHP for 2 of 11 years for nonfederal hospitals and for 3 of 10 years for clinics; the forecasts for nonfederal hospitals and clinics were directionally accurate 27.3% and 60.0% of the time, respectively. The mean absolute errors of the AJHP -published drug expenditure forecasts for the nonfederal hospital and clinic sectors were 2.0 and 4.7 percentage points, respectively. The CMS forecasts of overall drug spending were directionally accurate 70% of the time, and the mean absolute error (2.2 percentage points) was not statistically different from that of either sector forecast published in AJHP . Conclusion The annual drug expenditure forecasts published in AJHP have been reasonably accurate for predicting growth in prescription expenditures when compared with other available drug expenditure forecasts.
Published: 2015

34. High doses wireless radiation sensor using electromagnetic transducers

Author: Jan Dziuban, M. Matusiak, Patrick Pons, M. Olszacki, Hervé Aubert, A. Rifai, Émilie Debourg, I. Augustyniak, P. Knapkiewicz, Équipe MIcro et Nanosystèmes pour les Communications sans fil (LAAS-MINC), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT), Équipe Services et Architectures pour Réseaux Avancés (LAAS-SARA), Wroclaw University of Science and Technology, Department of Medical Protein Research, VIB, Department of Biochemistry, Universiteit Gent = Ghent University (UGENT), National Center for Nuclear Research (NCBJ), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Institut National des Sciences Appliquées (INSA), and Universiteit Gent = Ghent University [Belgium] (UGENT)
Subjects: Materials science, business.industry, Radiation sensor, passive electromagnetic sensors, Hydrogen pressure dosimetry, Nuclear radiation, Pressure sensor, nuclear radiation sensor, [SPI]Engineering Sciences [physics], Transducer, High doses, Optoelectronics, Radiation monitoring, Wireless, business
Abstract: International audience; This communication reports the last results obtained on the development of a wireless passive chipless sensor for high doses radiation monitoring. The sensor is based on polymer out-gazing inside a micro-chamber coupled with electromagnetic pressure transducer. Previous results on test structures have validated the principle of polymer out-gazing under nuclear radiation. An hermetic sealed prototype including the micro-chamber and the pressure transducer is reported here for the first time. This sensor has been fabricated successfully. Experimental results are reported and discussed.
Published: 2015

35. Spending on Hepatitis C Antivirals in the United States, 2008-2014

Author: Robert J. Hunkler, Linda M. Matusiak, Glen T. Schumock, Katie J. Suda, and Lee C. Vermeulen
Subjects: business.industry, Health Policy, medicine, Public Health, Environmental and Occupational Health, Hepatitis C, medicine.disease, business, Virology
Published: 2015
Full Text: View/download PDF

36. Antibiotic Expenditures by Medication Class and Healthcare Setting in the United States, 2010–2013

Author: Glen T. Schumock, Katie J. Suda, Lauri A. Hicks, Robert J. Hunkler, Rebecca M. Roberts, and Linda M. Matusiak
Subjects: Gerontology, Class (computer programming), medicine.medical_specialty, Infectious Diseases, Oncology, business.industry, medicine.drug_class, Family medicine, Health care, Antibiotics, medicine, business
Published: 2015

37. Thin-film transmission spectra of liquid benzylidenemethylamine and o-hydroxybenzylidenemethylamine in the infrared region

Author: M Matusiak, W. Wrzeszcz, Jerzy P. Hawranek, and Teresa Dziembowska
Subjects: Thin layers, Infrared, Chemistry, Organic Chemistry, Analytical chemistry, Spectral line, Analytical Chemistry, Inorganic Chemistry, symbols.namesake, Transmission (telecommunications), Near infrared spectra, symbols, Thin film, Raman spectroscopy, Refractive index, Spectroscopy
Abstract: The spectrum of the complex refractive index in the NIR and MIR regions was determined for liquid benzylidenemethylamine and intramolecularly hydrogen-bonded 2-hydroxybenzylidenemethylamine from transmission studies. In the MIR region very thin layers with thicknesses of a few micrometers had to be used to obtain reliable data. FT-Raman spectra of the liquids are also reported. Numerous bands were identified in both liquids basing on literature data and results of calculations. The effect of H-bond formation on the shift and intensity changes of bands were discusssed.
Published: 2004

38. Wireless passive high-doses radiation sensor

Author: Émilie Debourg, I. Augustyniak, Jan Dziuban, M. Matusiak, Patrick Pons, A. Rifai, M. Olszacki, Hervé Aubert, P. Knapkiewicz, Denis Lavielle, and C. Chatry
Subjects: Silicon membrane, Microelectromechanical systems, Dosimeter, Materials science, business.industry, Radiation sensor, Deflection (engineering), High doses, Wireless, Optoelectronics, Academic community, business
Abstract: The high dose measurement techniques are of the great interest in nuclear engineering for both, industrial and academic community. Related to these very harsh environment, today sensors solutions are based on external post analysis that not allow real time monitoring. Wireless monitoring of fully chipless passive sensors has been demonstrated for the first time using miniaturized HPD (Hydrogen Pressure Dosimitry) solution. We obtained micrometric silicon membrane deflection for several ten of kGy using 6MeV electron beam.)
Published: 2014

39. Early reoccurrence of fetal ED-A+ Fibronectin and B+ Tenascin-C splicing variants after human cardiac transplantation: potential impact for targeted therapy of chronic rejection

Author: André Renner, Marcus Franz, P. Richter, Jan Gummert, M. Matusiak-Brückner, H. Maschek, Katja Grün, Hans R. Figulla, Alexander Berndt, and Uwe Schulz
Subjects: Pulmonary and Respiratory Medicine, Fetus, Potential impact, biology, business.industry, medicine.medical_treatment, Tenascin C, Targeted therapy, Fibronectin, Transplantation, Immunology, RNA splicing, biology.protein, Cancer research, Medicine, Surgery, Cardiology and Cardiovascular Medicine, business
Published: 2014

40. Cotton Maturity and Its Influence on Nep Formation

Author: I. Frydrych, M. Matusiak, and T. Świech
Subjects: 010302 applied physics, Engineering, Polymers and Plastics, business.industry, Process (engineering), Astrophysics::Instrumentation and Methods for Astrophysics, 02 engineering and technology, Yarn, Raw material, 021001 nanoscience & nanotechnology, 01 natural sciences, Maturity (finance), Mathematics::Logic, visual_art, 0103 physical sciences, visual_art.visual_art_medium, Chemical Engineering (miscellaneous), Composite material, 0210 nano-technology, Process engineering, business, Spinning
Abstract: The nep number in yarn depends on both the nep number in the raw material and changes in the number and size of neps in the spinning process. Therefore, the two problems need to be analyzed separately. The first problem consists of testing the value changes of some cotton parameters on different processing stages, which influence the appearance and quality of rotor yarns made from different raw materials. The second problem is an analysis of the reasons for mechanical nep creation in raw materials and during processing. In order to explain the phenomenon of mechanical nep formation, which in our opinion is related to fiber buckling, we derive the theoretical relationship between the cotton fiber maturity parameter, called the coefficient of circularity, and the minimal inertia radius of a fiber cross section, assuming both ellipse and flattened ring shapes of fiber cross sections. The correlation coefficients between the mechanical nep number and the other cotton fiber parameters are determined. The minimal inertia radius and maturity ratio are significantly correlated with the mechanical nep number in raw material. We can draw a hypothesis that the minimal inertia radius and fiber slenderness are the most relevant parameters for mechanical nep formation during processing.
Published: 2001

41. MEMS high-doses radiation sensor

Author: P. Knapkiewicz, M. Olszacki, Jan Dziuban, M. Matusiak, Patrick Pons, I. Augustyniak, Faculty of Microsystem Electronics and Photonics, Wroclaw University of Science and Technology, National Center for Nuclear Research (NCBJ), Équipe MIcro et Nanosystèmes pour les Communications sans fil (LAAS-MINC), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), and Université de Toulouse (UT)
Subjects: Microelectromechanical systems, chemistry.chemical_classification, high dose radiation, Materials science, Hydrogen, Silicon, business.industry, chemistry.chemical_element, 02 engineering and technology, Polymer, polyethylene degradation, Radiation, 021001 nanoscience & nanotechnology, 01 natural sciences, 010309 optics, Membrane, chemistry, 0103 physical sciences, Optoelectronics, MEMS radiation sensor, High-density polyethylene, Irradiation, [SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics, 0210 nano-technology, business
Abstract: International audience; New MEMS sensor for detection of high doses (above 10 kGy) of radiation has been presented. The sensor is made of silicon and glass in a form of anodically bonded sandwich 9 × 16 × 2.6 mm3. The sensor contains chamber with small portion of high density polyethylene (HDPE) and thin silicon membrane. Irradiation releases gaseous hydrogen, which flows from the chamber to the membrane. For known radiation dose pressure of hydrogen destroys the membrane, what is optically noticed. The sensor show good detectability of doses of radiation up to 120 kGy.
Published: 2013

42. Projecting future drug expenditures in U.S. nonfederal hospitals and clinics--2013

Author: Fred Doloresco, Edward C. Li, Nilay Shah, Robert J. Hunkler, James M. Hoffman, Linda M. Matusiak, Lee C. Vermeulen, and Glen T. Schumock
Subjects: Pharmacology, Drug, Prescription drug, business.industry, Health Policy, media_common.quotation_subject, Pharmacy, Ambulatory Care Facilities, Drug Costs, United States, Expert opinion, Medicine, Humans, Medical prescription, Economics, Hospital, Health Expenditures, business, media_common, Demography, Rate of growth, Forecasting
Abstract: Purpose Factors likely to influence drug expenditures, drug expenditure trends in 2012, and projected drug expenditures for U.S. nonfederal hospitals and clinics in 2013 are discussed. Methods Prescription drug expenditure data for 2011 through September 2012 were obtained from the IMS Health National Sales Perspectives database. Expenditure projections were based on a combination of quantitative and qualitative analyses, combined with expert opinion. Results Total prescription sales in the United States for the 12-month period ending September 2012 were $326.0 billion, a 0.8% increase from the previous 12 months. This rate of growth was the lowest in recent history and can be attributed to modest increases in expenditures for new products (3.3%) and the prices of existing products (5.9%), coupled with a marked decline in overall volume and mix (−8.4%). For the 9 months ending in September 2012, total prescription expenditures grew 2.7% when compared with the same period in 2011. Oncology products remained important expenditures for hospitals and clinics. Antineoplastic agents were the top medication class for expenditures in nonfederal hospitals, and oncology products accounted for 32.2% of drug expenditures in the clinic setting in the first 9 months of 2012. Conclusion For 2013, we project a 1–3% increase in total drug expenditures across all settings, a 2–4% increase in expenditures for clinic-administered drugs, and a 0.5% decline to 1.5% increase in hospital drug expenditures. Health-system pharmacy leaders should carefully examine their own local drug-utilization patterns to determine their own organization’s drug expenditure forecast. Am J Health-Syst Pharm. 2013; 70:525–39
Published: 2013

43. Decay chains and photofission investigation based on nuclear spectroscopy of highly enriched uranium sample

Author: W. Czarnacki, M. Klimasz, Marek Moszynski, M. Kowalczyk, M. Kisieliński, A. Syntfeld-Kazuch, M. Matusiak, J. Mierzejewski, T. Abraham, P. Sibczyński, J. Srebrny, K. Kosinski, and J. Kownacki
Subjects: Nuclear reaction, Radiation, chemistry, Isotopes of uranium, Radiochemistry, Photofission, Uranium-235, chemistry.chemical_element, Gamma spectroscopy, Decay chain, Uranium, Enriched uranium
Abstract: Nuclear spectroscopy experiments were performed for 100 g metallic uranium rod enriched to 93% 235U, in order to establish and characterize the most prominent γ -rays in the natural decay series and photofission reaction. Single γ -ray spectra and γ – γ coincidences measurements were conducted before irradiation. The uranium sample was subsequently irradiated with 15 MeV bremsstrahlung photons. Relative intensities of γ -lines and several values of half-lives of the fission fragments decays were determined. The obtained information can be utilized in detection of smuggled nuclear materials and characterization of bulky nuclear waste packages.
Published: 2012

44. Projecting future drug expenditures--2012

Author: Fred Doloresco, Glen T. Schumock, Edward C. Li, Lee C. Vermeulen, Nilay Shah, Linda M. Matusiak, James M. Hoffman, and Robert J. Hunkler
Subjects: Drug, Prescription drug, media_common.quotation_subject, Summary data, Economic shortage, Pharmacology, Drug Costs, Ambulatory care, Environmental health, Outpatient setting, Ambulatory Care, Medicine, Drugs, Generic, Humans, Medical prescription, Economics, Hospital, Drug Approval, media_common, business.industry, Health Policy, Biosimilar, United States, Pharmaceutical Preparations, Health Expenditures, business, Forecasting
Abstract: Purpose Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. Summary Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7%, with total spending rising from $299.2 billion to $307.5 billion. Drug expenditures in clinics grew by 6.0% from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5% from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3% compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequently used medications. At the end of 2010, generic drugs accounted for 78% of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. Conclusion For 2012, we project a 3–5% increase in total drug expenditures across all settings, a 5–7% increase in expenditures for clinic-administered drugs, and a 0–2% increase in hospital drug expenditures.
Published: 2012

45. Projecting future drug expenditures: 2011

Author: Glen T. Schumock, Linda M. Matusiak, James M. Hoffman, Fred Doloresco, Nilay Shah, Cory E. Fominaya, Lee C. Vermeulen, and Robert J. Hunkler
Subjects: Pharmacology, Drug, business.industry, Health Policy, media_common.quotation_subject, Biosimilar, Recession, Drug Costs, United States, Ambulatory care, Pharmaceutical Preparations, Environmental health, Health care, Outpatient setting, Fees, Pharmaceutical, Medicine, Humans, Health care reform, Medical prescription, business, Drug Approval, media_common
Abstract: PURPOSE. Drug expenditure trends in 2009 and 2010, projected drug expenditures for 2011, and factors likely to influence drug expenditures are discussed. SUMMARY. Various factors are likely to influence drug expenditures in 2011, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, and biosimilars. Two distinct patterns of drug expenditures continue to exist. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction of generic medications for high-cost, frequently used medications and the influence of the economic downturn. The second pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting. The influence of health care reform, the economy, and the emergence of biosimilars will be important trends to follow over the next several years, but they are unlikely to have substantial impact on drug expenditures in 2011. From 2008 to 2009, total U.S. drug expenditures increased by 5.2%, with total spending rising from $284.8 billion to $299.5 billion. Growth in drug expenditures in clinics grew by 5.1% from 2008 to 2009. Hospital drug expenditures increased at the moderate rate of 2.8% from 2008 to 2009; through the first nine months of 2010, hospital drug expenditures increased by only 0.8% compared with the same period in 2009. CONCLUSION. For 2011, we project a 3-5% increase in drug expenditures in outpatient settings, a 4-6% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.
Published: 2011

46. Nernst effect measurements of epitaxial Y0.95Ca0.05Ba2(Cu1-xZnx)3Oy and Y0.9Ca0.1Ba2Cu3Oy superconducting films

Author: I, Kokanović, J R, Cooper, and M, Matusiak
Abstract: We report Nernst effect data for crystalline films of Y0.95Ca0.05Ba2(Cu1-xZnx)3Oy (with x=0, 0.02, and 0.04) and Y0.9Ca0.1Ba2Cu3Oy grown by pulsed laser deposition. We show that our own results and published data for LSCO are consistent with the theory of Gaussian superconducting fluctuations. We also show that Zn doping increases the Nernst coefficient simply because it reduces the in-plane conductivity.
Published: 2008

47. Migration modelling of dangerous PM2,5 and PM10 dust pollutants in air generated during forest fires

Author: M. Matusiak, M. Mazurek, and S. Jędraszko
Subjects: Environmental science
Published: 2015

48. Blood lead levels in NASCAR Nextel Cup teams

Author: Gregory K. Steele, Matthew M. Matusiak, Joseph O'Neil, Jyl Madlem, and C. Scott McNair
Subjects: Adult, Male, Automobile Driving, Demographics, Health outcomes, Risk Assessment, Environmental health, Occupational Exposure, Medicine, Humans, Lead (electronics), Demography, Vehicle Emissions, business.industry, Public Health, Environmental and Occupational Health, Middle Aged, Automobile driving, United States, Job Description, Lead, Relative risk, Lead exposure, Female, Occupational exposure, business, Automobiles, Sports
Abstract: This pilot study determines whether NASCAR racing teams demonstrate exposure to lead from exhaust by evaluation of blood lead levels (BLL). Participants were stratified by proximity to fuel exhaust or whether they worked on an engine. Each participant completed a self-reported survey recording demographics, lead exposure (occupational or in-home environment), and any physical symptoms of lead toxicity. Blood lead levels were then measured. BLL of 47 individuals ranged from 1-22 microg/dL with a median of 9.4 microg/dL. Nineteen of 47 (40.4%) had BLLor = 10 microg/dL. Participants exposed to exhaust gas had the highest relative risks (RR) for elevated lead, followed by working on brakes and radiator repair. The RR of having an elevated BLL and self-reported adverse health outcomes or symptoms was increased. This study of NASCAR racing teams demonstrates lead exposure.
Published: 2005

49. Effect of woven fabrics on the fabric hand of cotton and CO/PES fabrics assessed on the Instron tensile tester

Author: M Matusiak and I Frydrych
Subjects: Clothing industry, Materials science, Composite material, Fabric structure, Tensile testing
Abstract: Publisher Summary Fabric hand is a property assessed very often in daily life, providing information mostly for the finishing and clothing industry. This chapter shows that objective hand tests made on a very complicated and expensive system can be replaced by less complicated tests done on the Instron tensile tester; and it presents the derivation of General Hand Factor [“GHF”] for such measurements. In order to elaborate the GHF and to assess the influence of fabric structure factors on the GHF value, raw fabrics characterized by different weaves and different cover factor values resulting from the different weft density values were produced; next, they were finished using two types of finishing. The chapter outlines the problem concerning the main factors that influence fabric hand. It also presents the results of tests on mechanical properties under small stresses for cotton and CO/PES fabrics.
Published: 2005

50. An Experimental Study of Strength and Ductility of Welded Aluminium Beams

Author: M. Matusiak and P.K. Larsen
Subjects: Materials science, chemistry, law, Aluminium, Metallurgy, chemistry.chemical_element, Welding, Ductility, law.invention
Published: 1999

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

119 results on '"M. Matusiak"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources